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Abstract 
The tricarboxylic acid (TCA) cycle is a central route for the energy production via 
oxidative phosphorylation and is ubiquitous throughout nature. Apart from playing a major role 
in energy provision, it is also essential for a wide range of physiological functions in any 
organism. Although an increasing emphasis is laid on the interlinking role of the cycle, its 
regulation and control are less very less understood. As the field progresses, the consequences of 
TCA cycle anomalies are shown to be tied to various cancers and other disorders. The matter 
becomes more complex when considering the varying functions of the isozymes present in the 
cycle. 
The repertoire of twenty amino acids that is present in almost all organisms makes up for 
the hundreds of proteins responsible for the basic functioning of an organism. In order to 
synthesize a wide spectrum of viable proteins, one of the methods that the cells utilize is post-
translational modifications. These modifications can be reversible depending on the conditions 
and they render conformational changes to the protein, thereby influencing its enzyme activity or 
labeling them for transportation or degradation. One such post-translational modification is 
acetylation, which is the main focus of this project. Acetylation is predominantly seen across all 
domains of life, and in spite of the prevalence of this modification, it is only recently that with 
the advances in technology the basic role of acetylation is being understood. However, there are 
still many questions that need to be answered to recognize the complete role of protein 
acetylation. 
Recently, a newer technique has been adopted to study the impact of post-translational 
modifications. The genetic code expansion strategy helps in the incorporation of a noncanonical 
amino acid into a distinct position, thereby giving rise to a customized protein. It uses stop codon 
 
 
suppression to insert the unnatural amino acid. The pyrrolysyl-tRNA synthetase and its cognate 
tRNA were used in this project to create TCA cycle enzymes with acetyllysine.  
In this dissertation, I examine the changes caused in the enzymes, malate dehydrogenase, 
isocitrate dehydrogenase, and citrate synthase, of the TCA cycle in response to acetylation of 
specific lysine residues and deduce the potential mechanisms regulating these changes. In doing 
so in E. coli, a greater understanding of protein acetylation is achieved and its implications on 
modulating functions are examined.  
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1 
CHAPTER I 
INTRODUCTION  
1.1 Tricarboxylic Acid Cycle 
The tricarboxylic acid (TCA) cycle also called the citric acid cycle or the Kreb’s cycle is 
a central pathway consisting of a series of steps for the oxidation of acetyl CoA to release 
adenosine triphosphate (ATP) and carbon dioxide (CO2) (Figure 1.1).  
 
Figure 1.1 Schematic representation of TCA cycle. It shows the reactions facilitated by eight 
enzymes in the mitochondrial matrix of eukaryotes [1]. The cycle results in the production of 
NADH and FADH2 which in turn donate electrons via electron transport chain (ETC) to generate 
ATP from oxidative phosphorylation. 
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The Kreb’s cycle was first proposed in 1937 by Hans Adolf Krebs, a German-British 
scientist who later was awarded the Noble Prize in physiology in 1953.  It is an energy-
producing pathway of the respiratory metabolism that produces NADH and FADH2, which will 
be channeled to the electron transport chain in the mitochondria of eukaryotes [2].  
In prokaryotes, this sequential process is performed in the cytosol with the proton 
gradient for ATP being made across the cell membrane. A similar pathway in the eukaryotes 
occurs, with the difference that the reaction takes place in the mitochondrial matrix. Two rounds 
of the citric acid cycle have an overall yield of 6 NADH, 2 FADH2, and 2 ATP which accounts 
for 24 ATP in total [3].  
Apart from its role in respiration, amino acid biosynthesis, and nitrogen metabolism in 
plants, TCA cycle also impacts cellular redox balance and biotic stress responses [4]. It is an 
exergonic in nature and predominant in aerobic organisms. The evolutionary origin of the TCA 
cycle is long considered to be a reductive version of it rather than the commonly observed 
oxidative one. The reductive form is a non-Calvin type of carbon dioxide fixating pathway seen 
in organisms like Aquificales and was first reported in Chlorobium limicola, a green sulfur 
photosynthetic bacteria [5].  
Although the TCA cycle is most times considered to be a unidirectional route, there are 
other pathways that the metabolites can follow from or into. This is simply proven by the fact 
that the only reactions that are irreversible in the cycle are mediated by citrate synthase and -
ketoglutarate dehydrogenase [6]. An extraordinary role of connecting gluconeogenesis, 
transamination, deamination, and lipogenesis is accomplished by the TCA cycle [7] however, 
unlike other metabolic pathways, very few genetic disorders and diseases associated with the 
TCA cycle are known. Nevertheless, it is also to be noted that in the recent years, many research 
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groups are actively involved in emphasizing the versatility of this pathway and the intricacies it 
poses in maintaining the homeostasis of the body.  
 
1.1.1 Evolution of the TCA cycle 
It has always been intriguing to unravel the factors that stimulated the origin of life on 
earth. The proof of cellular life dates back to somewhere between 3.5 to 4 billion years ago [8], 
but the earth was shown to be reducing or neutral only 2 billion years ago [9]. The basis to 
comprehend the beginning of life forms lies in investigating the emergence of the metabolic 
pathways. It is considered that protein cofactors would have mediated the proto-metabolic 
reactions even before the protein-mediated pathways came into existence. In some cases, 
Fe/Ni/S-electron transfer cofactors that function in relation to the acetyl CoA pathway enzymes 
still bear some comparisons to the reactive geological period [10].  
 
Figure 1.2 Representation of the reductive TCA cycle. It is considered the precursor of the 
oxidative cycle and helps in carbon dioxide fixation and serves to stir the production of major 
biomolecules [11].  
 
TCA cycle is the most studied pathway to understand early life [12]. Enzymes of the 
TCA cycle are considered ancient from its homology that is seen across bacteria, archaea, and 
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eukaryotes. Ever since, researchers have proposed many variants of the TCA cycle which 
include 1) reductive TCA cycle, 2) alternative oxidative cycle, and 3) variant with 
acetate:succinate CoA-transferase (ASCT) instead of succinyl-CoA synthetase [13]. The 
oxidative direction of the TCA cycle transforms organic compounds into reducing counterparts. 
These assist biosynthetic reactions that maybe otherwise unfavorable or participate in ATP 
production through oxidative phosphorylation. The reductive TCA (rTCA) cycle, also called the 
reverse Krebs cycle, or Arnon cycle helps in the fixation of carbon dioxide [14]. rTCA is the 
precursor of an aerobic TCA cycle leading to the synthesis of amino acids, carbohydrates, lipids, 
nucleobases, and other metabolic intermediates [10] (Figure. 1.2).  
Mycobacterium has always raised ambiguities in understanding its pathogenesis and 
other metabolic functioning. Traditionally, the TCA cycle in aerobic and anaerobic organisms 
distinctly varies. Contrarily, Mycobacterium tuberculosis (M. tb) is known to survive under 
drastic hypoxic conditions (0.28 mm Hg i.e., 0.03%), while being an aerobic bacterium [15]. 
This drew attention to the possibilities of variation of the TCA cycle in M. tb. Previously, it was 
indicated that α-ketoglutarate dehydrogenase was absent in M. tb and so, the succinic 
semialdehyde (SSA) variant of TCA cycle was assumed to be functional. On the contrary, 
recently, researchers have identified CoA-dependent α-ketoglutarate dehydrogenase in M. tb, 
which is typically found in anaerobic bacteria. This ketoglutarate: ferredoxin oxidoreductase 
(KOR) is tested to be highly stable even under aerobic conditions, which is exceptional to other 
enzymes in this family. KOR has been shown to complete the oxidative TCA in M. tb with two 
pathways: 1) KOR dependent in the presence of β-oxidation and 2) succinic semialdehyde 
dependent in the absence of β-oxidation [16].  
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The variants seen in the TCA cycle imposes its significance across all life forms and it 
becomes inevitable to study in detail the regulation of this cycle and its role in maintaining the 
delicate balance of metabolites.  
 
1.1.2 Role of TCA cycle in the synthesis of biomolecules 
Metabolites produced as a result of TCA cycle form precursors for a number of 
biomolecules including amino acids, nucleic acids, fatty acids, and porphyrins. This shows the 
amphibolic nature of the cycle as it performs both catabolism and anabolism.  
 
Amino Acids biosynthesis 
All amino acids are synthesized as a resultant from the intermediates of glycolysis, citric 
acid cycle, or pentose phosphate pathway. While organisms like E. coli can synthesize all 20 
amino acids, humans depend on dietary supplementation of 9 essential amino while the others 
are called non-essential amino acids. 
α-ketoacids, α-ketoglutarate, and oxaloacetate of the TCA cycle play a vital role in the 
production of amino acids. The hexameric enzyme glutamate dehydrogenase (GDH) catalyzes 
the reversible conversion of α-ketoglutarate and ammonia to glutamate [17].  
            NH4
+ + α-ketoglutarate + NADPH +H+ ⇌ glutamate + NADP+ +H2O 
Consequently, the amino group from glutamate is transferred to other metabolites such as 
oxaloacetate in the case of TCA cycle, by transamination reaction to produce aspartate. These 
reactions are catalyzed by pyridoxal phosphate-dependent transaminases [18].  
           Oxaloacetate + glutamate ⇌ aspartate + α-ketoglutarate 
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Conversion of aspartate and glutamate to asparagine and glutamine, respectively are 
chemically analogous [19]. Biosynthesis of proline, which is a cyclized derivative of glutamate, 
is obtained by the reaction between ATP and γ-carboxyl group of glutamate yielding an acyl 
phosphate. This, in turn, is reduced to glutamate γ-semialdehyde, which is cyclized and reduced 
to form proline. The glutamate γ-semialdehyde in this pathway can also form arginine without 
cyclization. Other amino acids namely, methionine, threonine, and lysine are synthesized from 
aspartate [20]. 
 
Porphyrins biosynthesis 
Porphyrins which are necessary for the formation of heme and chlorophyll are 
synthesized by the condensation reaction of glycine and succinyl-CoA. The product of this 
reaction, δ-aminolevulinate, is formed by the catalysis of δ-aminolevulinate synthase and shapes 
the basis for the complex structure of porphyrins[21]. Recently, it has been studied that during 
late phases of erythropoiesis, δ-aminolevulinate could undergo deamination with glutamine as its 
precursor, and lead to the conversion of α-ketoglutarate to succinyl-CoA catalyzed by α-
ketoglutarate dehydrogenase (KDH). This process is suggested to take place without passage 
through the TCA cycle but with the direct involvement of δ-aminolevulinate synthase and KDH 
[22]. 
 
1.1.3 Role of TCA cycle in other processes 
Interplay of the TCA cycle is observed in many processes other than just metabolism. 
This is distinct from the anaplerotic nature of the pathway and its discrete function in different 
cells for different conditions. The critical features of mitochondrial regulations are survival, 
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activation, and differentiation of immune cells [23]. The functioning of M2 macrophages 
involved in anti-inflammatory responses is dependent on the completion of the TCA cycle, while 
M1 macrophages break the pathway into two stages to accumulate itaconate, a microbicide 
compound, and succinate which aids in hypoxia inducible factor 1α (HIF1α) stabilization [24, 
25]. Furthermore, many TCA cycle metabolites are suggested to function as inflammatory 
response biomarkers for autoimmune diseases, sepsis, and systemic infection [26]. It has also 
been indicated that in the diabetic state, energy metabolism including glucose absorption and 
TCA cycle is disrupted for which many medicinal plants are studied by researchers to maintain 
homeostasis of pyruvate, which in turn would increase the metabolites of TCA cycle [27]. 
Apart from the direct involvement of TCA in the immune response, the metabolites 
produced in the process render dendritic cells (DC) activation and other inflammatory functions. 
Acetyl CoA and oxaloacetate assist in the synthesis of fatty acids and sterols. This in turn plays a 
critical role in the membrane construction and expansion, required for DC antigen presentation. 
Expansion of endoplasmic reticulum and Golgi leads to the production of proteins necessary for 
the activation and functioning of macrophages [28].  
Modulation of TCA cycle metabolites in influenza A virus infected cells were studied to 
discover the value of immunometabolism. On infecting H1N1 virus into A549 adenocarcinomic 
human alveolar basal epithelial cells, it was found that enzymes of the TCA cycle remained 
intact during the first replication cycle (0-8 hours). It is implied that the stability of TCA cycle 
was crucial for viral replication and so the mitochondrial energy was maintained by up-
regulating the glutamate produced [29]. 
Isozymes of TCA cycle enzymes are present in mitochondria (isocitrate dehydrogenase 
[ICDH] 2) and cytosol (ICDH1 and malic enzyme/ME1) [30]. They are involved in the synthesis 
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of NADPH, which acts as a cofactor to reduce oxidized glutathione (GSSG→2GSH) and 
thioredoxin for glutathione reductase (GR) and thioredoxin reductase, respectively. Glutathione 
peroxidases (GPX) in the liver oxidizes glutathione and is an antagonist to GR. It has been 
studied that these biomolecules, glutathione and thioredoxin, play a role against oxidative stress 
[31] and promote endoplasmic reticulum (ER) protein synthesis.  
  
Figure 1.3 The illustration of the role of TCA cycle in ER stress. It shows the depiction where 
A. the mitochondrial pyruvate carrier (MPC) activation increased the NADPH production, 
thereby elevating ER stress. B. shows the deletion of MPC and the reduction in TCA cycle 
resulted in alleviation of ER stress and protected the liver from steatohepatitis in relation to 
glutathione peroxidase 1 (GPX1).  
When a disease such as obesity and its associated disorders disrupt the protein biogenesis 
process, it causes stress on ER. With further investigation into the direct role of TCA cycle on 
ER stress, it was found that inhibiting either TCA-dependent NADPH production or glutathione 
reductase aided in reducing ER stress (Figure 1.3). This data was corroborated when 
mitochondrial pyruvate carrier (MPC) was knocked out in hepatocytes to inhibit TCA cycle. It is 
understood that ER estimates mitochondrial metabolic activity with NADPH and GSSG levels. 
When acetyl CoA availability decreases, it leads to a reduction in NADPH and thus dampens 
A. 
B. 
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glutathione reduction. Consequently, ER oxidative state is altered, and ER homeostasis is 
maintained. This pattern is also visible in other cell types such as myocytes and brown 
adipocytes [32]. 
 
1.1.4 TCA cycle in cancer 
There have been developing evidence which point to the idea that cancer is mitochondrial 
in nature and mutations in TCA enzymes such as isocitrate dehydrogenase (ICDH), succinate 
dehydrogenase (SDH), fumarate hydratase (FH), and malate dehydrogenase (MDH) have been 
observed in some tumors [33, 34] (Table 1.1). This is caused by the imbalance in metabolites and 
cytoplasmic levels of acetyl CoA, thereby manipulating crucial proteins that cause tumorigenesis 
by acetylation [35]. Furthermore, acute myeloid leukemia is characterized by the involvement of 
TCA cycle with glutamine as its fuel [36]. On the contrary, there have also been studies 
suggesting that glutamine acts as a fuel for the TCA cycle may not confer tumor growth but the 
advantage may be interconnected to its relation with other pathways [37]. Additionally, 
hepatocellular carcinoma is also influenced by aconitase (ACO2) and ICDH with their interplay 
in the upregulation of NF-κB, HIF, and mitochondrial signals [38].  
 Lan Huang et al., have reviewed the role of citrate in the development, survival, and 
expansion of cancer. Citrate is known to play dual roles in tumor prognosis. There have been 
studies that support the anti-tumor effects of citrate showing a reduction in tumor size and 
proliferation rate. On the contrary, there have also been researches to show the tumor growth 
promotion and metastatic characteristics promoted by citrate. Recently, efforts to develop citrate 
as a biomarker for cancer diagnosis are being made, especially in the case of prostate cancer. 
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Understanding the vital role of citrate in cancer has in turn, led to the attention of citrate synthase 
(CS) and aconitase 2 (ACO2), which control the concentration and fate of citrate [28]. 
Role of TCA cycle in the production of monoclonal antibody (mAb) has been elucidated 
by examining Chinese hamster ovary (CHO) cells. CHO cells are predominantly used in the 
production of mAb but the bottleneck in this method is the Warburg effect that leads to excessive 
lactate production. To improve the efficiency of this process, stimulation of TCA cycle activity 
and mitochondrial respiration was tested. When α-lipoic acid, a pyruvate dehydrogenase 
activator, was used to aid the anaplerosis of this cycle, it showed process improvement but 
resulted in saturation of mitochondria. To balance this effect, the mitochondrial capacity was 
improved using methylene blue. The combinational use of these drugs yielded an 24% rise in 
mAb production with lowered stress signals [39]. Thus, the modulation of TCA cycle not only 
plays a role in metabolic regulation but indirectly controls a number of industrial applications.  
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Table 1.1 Depiction of different types of cancer which are caused by the dysfunction of 
some TCA cycle enzymes[33] [28]. 
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1.1.5 Enzymes of the TCA cycle concentrated on in this project 
1.1.5.1 Malate Dehydrogenase 
Malate dehydrogenase, an enzyme of the TCA cycle, reversibly oxidizes L-malate 
(MAL) to oxaloacetate (OAA) accompanied by the conversion of NAD+ to NADH [40]. This 
enzyme is present in many isoforms most of which are NAD+-dependent except for the MDH 
isoform present in the chloroplast which is NADPH dependent. In eukaryotes, MDH1 and 
MDH2 are present in the cytoplasm and mitochondria, respectively. MDH2 is the enzyme that 
participates in the TCA cycle, while MDH1 is the enzyme in the malate/aspartate shuttle. Both 
isozymes are present as dimers with molecular mass of the monomer being ∼35 kDa and is 
allosterically regulated by citrate, while inhibited by 2-thenoyltrifluoroacetone, adenosine mono-, 
di-, tri-phosphate, fumarate, citrate, and aspartate, and high OAA concentrations [41]. Another 
isoform which converts malate from glyoxylate cycle in yeast is present in the glyoxysomes. 
MDH2 in eukaryotes is analogous to the MDH present in some eubacteria such as E. coli and 
MDH present in chloroplast and cytoplasm show sequence similarities with other eubacteria 
including Thermus flavus. This fact favors the endosymbiotic theory for the evolution of 
mitochondria and chloroplasts [42].  
Structurally, MDHs are stable dimers consisting of structural and functional domains of 
each subunit. The N-terminal consists of the NAD+-binding domain with a parallel β-sheet 
structure, while the C-terminal comprises of the substrate binding domain and two domains are 
attached to each other with a cleft that forms the active site of the enzyme [42].  
MDH has been implicated with a number of processes that cause various diseases. In 
cancer, there have been evidence to support that both MDHs present in the mitochondria and 
cytoplasm could be potential targets against cancers to maintain the required redox states [43]. It 
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has also shown that MDH1 regulates early stages of autophagy responsible in pancreatic ductal 
adenocarcinoma survival [44]. In a degenerative disorder like Creutzfeldt-Jakob disease, 
mitochondrial MDH has been expressed at elevated levels than in comparison to the control 
paving ways to be used for diagnostic purposes [45]. Similarly, anomalies in both MDH1 and 
MDH2 have been associated with the early onset of severe encephalopathy [46] [47]. In addition, 
MDH also plays a role in metabolic diseases such as diabetes and helps in gaining further 
knowledge on the pathogenesis of Mycobacterium [48, 49] and Brucella [50]. These studies, 
therefore, prove MDH to be a potential candidate to develop therapeutics by understanding its 
role in maintaining homeostasis. 
 
1.1.5.2 Isocitrate Dehydrogenase 
Isocitrate dehydrogenase is a crucial enzyme associated with many types of cancers. It 
has three isoforms: ICDH1 located in the cytoplasm and peroxisomes and ICDH2 and ICDH3 in 
the mitochondria. 
ICDH1 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate 
accompanied with the conversion of NADP+ to NADPH reversibly, while the same reaction is 
carried out in the mitochondria by ICDH2. Structurally, both enzymes are homodimers and play 
an important role in oxidative stress. Alternatively, the reverse reaction influences lipogenesis 
and glycolysis regulation. In contrast to ICDH1 and ICDH2, ICDH3 catalyzes the irreversible 
oxidative decarboxylation of isocitrate to α-ketoglutarate with the reduction of NAD+ to NADH. 
This isoform is a heterotetramer consisting of two α-subunits, one β, and one γ-subunit and is 
subjected to allosteric regulation. It is activated by calcium, ADP, and citrate, while inhibited by 
ATP, NADH, and NADPH [51].  
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Increasing interest in the impact of ICDH on cancer is fast growing because of its 
diagnostic and prognostic value [52]. In the last decade, nearly 3000 research papers have been 
published that interrelate the functions of ICDH to cancer. Aberrant ICDH expression has been 
observed in acute myeloid leukemia, angioimmunoblastic lymphomas, chondrosarcoma, gliomas 
[53], intrahepatic cholangiocarcinoma, and thyroid carcinomas [54]. In most cancer, mutations of 
ICDH1/2 have only been observed, while ICDH3 has no noticeable impact on cancer. When a 
mutation takes place in ICDH, it results in the formation of a neomorphic enzyme that 
accelerates the conversion of α-ketoglutarate to D-2-hydroxyglutarate (D2HG) and accumulation 
of D2HG is used as a biomarker to identify such aberrations. Many drugs have been developed 
to inhibit the activity of ICDH1/2 and are being tested at different stages of clinical and pre-
clinical studies. It has also been suggested that ICDH alter the expression of immunogenic 
cytokines and receptors, thereby making it a target for immunotherapy. Thus, immediate stress is 
laid on comprehending the ways to modulate ICDH activity and mutations to deliver therapeutic 
approaches that benefit against cancer. 
 
1.1.5.3 Citrate Synthase 
 Citrate synthase (CS) is the first enzyme in TCA cycle and is a rate-limiting enzyme. As 
the TCA cycle occurs in the matrix of the mitochondria, CS is transported from the cytoplasm to 
the mitochondria and is known to play a pivotal role in producing energy and apoptosis in 
different cell types. Two isoforms of CS are identified in the mitochondria and peroxisomes of 
Saccharomyces cerevisiae and Arabidopsis thaliana [55]. Modulation of expression levels of CS 
has a direct effect of ATP production, excessive superoxide formation and cell apoptosis [56]. 
The importance of CS in the pathogenesis of various organisms has been studied including 
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Klebsiella pneumonia [57] and Echinococcus granulosus [58]. CS plays a specific role in renal 
health and it is suggested that there could be a viable defense against progressive renal injury 
under decreased CS activity [59]. It has been studied that CS is connected to the Warburg effect 
causing malignancy [60] and is also linked to different cancers including pancreatic, ovarian, 
cervical, and breast cancer. It can either be characterized by increased or decreased activity 
depending on the tissue type [28]. With increasing evidence suggesting the role of CS in 
tumorigenesis and other processes, it becomes important to investigate the consequences of 
manipulating its expression and enzyme activity under varying conditions.  
 
1.2 Post-translational Modification 
Commonly the 20 natural canonical amino acids are encoded by 61 triplet codons in 
addition to the three stop codons. While these amino acids make up for the complete protein 
composition in most organisms, for them to become functionally capable to carry out different 
processes they undergo further modifications, either co-translationally or post-translationally. 
Post-translational modifications (PTMs) play a pivotal role in regulating protein activity, 
compartmentation, transcription, and cellular signaling and the major PTMs include 
phosphorylation, acetylation, methylation, and ubiquitination [61] (Figure 1.4). 
 
1.2.1 Implications of PTMs in the human body 
The diversity of peptide modifications is long-established, but a renaissance of interest 
has been noticed in understanding their role in molecular mechanisms that control homeostasis 
of the body. These new insights answer questions that help connect different pathways and 
networks that control fundamental biological processes. Anomalies in PTMs lead to various 
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diseases such as neurodegenerative disease [62-64], heart disease [65], cancer [66, 67] and age-
related disorders [68, 69]. 
 
Figure 1.4 Schematic representation of different post-translational modifications. It depicts 
the modifications that can be separated into five general classes: reversible addition of chemical 
groups or complex molecules or polypeptides to specific amino acids and irreversible amino acid 
modification or cleavage of the peptide bond between residues, known as proteolysis [70]. 
 
1.2.2 Acetylation 
Acetylation is the transfer of acetyl group from acetyl CoA to the α-amino group of 
the N-terminus of proteins (irreversible) or to the ε-amino group of lysine amino acids 
(reversible) by N-acetyltransferase (NAT) and is reversibly removed by deacetylases. It is one of 
the major PTMs and has been found that nearly 80-90% of eukaryotic proteins are acetylated. In 
spite of the underpinning role of acetylation in different biological process including 
transcription, replication, recombination, repair, translation, apoptosis, stress control, and 
membrane trafficking [71], it is not until recently that the significance of acetylation is gaining 
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attention. Acetylation of histone proteins on chromatin regulates gene transcription and, in this 
case, histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyze the transfer 
of the acetyl group to and from an amino acid. Therefore, acetylation and methylation of histones 
affect the overall transcriptome of an organism. For other non-histone proteins, lysine 
acetyltransferases (KATs) and lysine deacetylases (KDACs) perform the addition and removal of 
acetyl group, respectively (Figure 1.5). Three families of KATs have been identified with 
members: GNAT family, MYST family, and p300/CBP (CREB-binding protein) family. 
 
Figure 1.5 Exemplification of the acetylation process. Acetyl CoA acts as an acetyl donor 
whereas KAT and KDAC execute the reversible transfer of acetyl group of the protein [72]. This 
reversible acetyl transfer is involved in the regulation of protein functions. 
Sirtuins are a family of NAD+ (nicotine adenine dinucleotide)-dependent deacetylases 
and functions in gene silencing by hypoacetylation and maintain genomic stability. The second 
family of KDACs is Zn2 +-dependent HDACs which consists of three classes: Class I, II, and IV 
[71]. They are concentrated in the nucleus and the cytoplasm, while sirtuins are also present in 
the mitochondria. It is also known to crosstalk with other PTMs such as phosphorylation, 
ubiquitination, and methylation [73].   
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To regulate Tau assembly and function, phosphorylation and acetylation appear to 
crosstalk. Tau liquid-liquid phase separation and aggregation is decreased on lysine acetylation. 
Also, phosphorylation of Tau is inhibited upon acetylation of Lys-321, thereby preventing its 
function and promoting aggregation. Similar mechanisms are detected in ribosome binding 
proteins such as TDP-43 [74] which make up the ribonucleoproteins. Recently, the role of 
acetylation, phosphorylation, and methylation in lung cancer were studied in an effort to develop 
new therapeutics for lung cancer patients and illustrate how the PTMs control different cell 
signaling pathways [75].  
 
1.2.2.1 Role of Lysine Acetylation in Physiology 
As lysine acetylation impacts many cellular processes, it is inevitable that it plays a role 
in influencing the physiology of an organism. When acetylation takes place with acetyl CoA as a 
donor, it releases negatively charged acetate anions decreasing the pH. In this condition, the 
histones become hypoacetylated and push the anions and protons outside the cell. Conversely, in 
actively proliferating cells, as the pH increases, histones are hyperacetylated. Furthermore, it has 
been observed that acetylation patterns vary in different cell types in diverse conditions.  
Neuronal activities undergo crosstalk of acetylation and phosphorylation through MAPK-ERK-
pathway and when this balance is disturbed, it leads to cognitive deterioration. Moreover, similar 
processes affect the pluripotency and cause developmental issues [76]. 
 
1.2.2.2 Role of Lysine Acetylation in Diseases 
Failure to maintain a tight balance between acetylation and deacetylation is associated 
with a number of clinical conditions such as neurodegenerative diseases, cancer, cardiac 
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hypertrophy, diabetes, autoimmune diseases, and asthma. It is caused by the dysfunction of 
KATs and KDACs which interlink different signaling pathways that affect cellular processes 
[71]. Some effects of acetylation and its involvement in diseases is given below: 
 
• Neurodegenerative Diseases 
As mentioned earlier, acetylation is known to play a significant role in Alzheimer’s 
disease. Studies have proven that acetylated tau protein is prone to aggregation and accumulation 
as the lysine residues assigned for ubiquitination are blocked, thereby preventing proteasomal 
degradation of aggregated proteins. Subsequently, microtubule assembly was also inhibited 
causing damage and leading to tauopathies [77]. Even in the case of schizophrenia, epigenetic 
modifications of histone acetylation have been observed [78].  
 
• Cancer 
Research shows that mutations or aberration in KATs and KDACs expression could lead 
to cancer development and therefore inhibitors of KATs and KDACs are being tested to treat 
cancers. It has also been recognized that acetylation profiles vary with different cell types in the 
same species and in cancer, depending on the type, these proteins can either behave as tumor 
promoters or tumor suppressors. Acetylation leading to cancers target transcriptional factors and 
are generally overexpressed. Myc, which is a family of proto-oncogenes that code for 
transcription factors, is also over expressed in cancers and is targeted for acetylation by a number 
of KATs. Similar mechanisms are also monitored in other tumor promoting factors making them 
a promising target against cancer. p53 is an important tumor suppressor protein that is acetylated 
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at different positions to affect diverse roles including DNA binding, proteasomal degradation, 
apoptosis, and cell cycle arrest.   
 
Class I and class II KDACs have been reported in cancer development. Sirtuins, on the 
other hand, have been linked to both tumor suppression and promotion. For instance, SIRT1 is 
overexpressed in prostate cancer and acute myeloid leukemia and targets tumor cell progression. 
Conversely, it plays the role of tumor suppression by deacetylating Myc proteins and thereby 
preventing the expression of oncogenes [79].  
 
• Aging 
Aging is a physiological change that results in a gradual decrease in the functional 
capacity of an organism. Aberrant acetylation is a hallmark observed in aging. Histone 
acetylation plays a critical role in regulating senescence and modulating longevity. Lysine 
acetylation on histones at positions H3K27 and H3K9 are observed with senescence. Similarly, 
higher acetylation is observed in neuronal immediate early genes, which in turn prevents the 
expression of these genes and maintains distinguishing memory. Autophagy dysfunction of 
which is also a sign of aging is linked to histone H3 acetylation increase [80].  
These studies show the role of acetylation in the functioning of the body, thereby making 
it an important target for therapeutics and also, understanding the impact of its regulation could 
help in generating better insights for various medical conditions. 
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1.3 Genetic Code Expansion 
 
Figure 1.6 An outline of the incorporation of non-canonical amino acids (ncAA) using 
genetic code expansion strategy. While the evolved aminoacyl–tRNA synthetase (aaRS) 
charges the tRNA with ncAA, the tRNA distinguishes the amber codon for ncAA integration 
into the designated site of the protein [81]. 
 
There are several limitations to studying PTMs of proteins. The dynamic nature of any 
PTM makes it challenging to isolate and characterize it. It also known that PTMs do not occur 
independently and also crosstalk with other PTMs on different residues. To learn the association 
between different modifications and the role of an individual modification on a specific residue 
become difficult. The solution to these setbacks could be in co-translationally incorporating the 
modified amino acids into proteins directly. The genetic code expansion strategy is applied in 
this project to homogeneously incorporate acetyllysine (AcK) at definite positions and monitor 
the effects caused by this modification.  
In nature, protein translation process in all living organisms is an interplay among 
transfer RNAs (tRNA), aminoacyl-tRNA synthetases (aaRS), messenger RNAs (mRNAs) triplet 
codons, and ribosomes. 20 amino acids are coded using the almost universal 61 codons and 
employ tRNAs charged with amino acids by aminoacyl-tRNA synthetase enzymes. The protein 
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sequence on mRNA is read through base pairing between codons of mRNA and anticodons of 
tRNA. The fidelity of decoding genetic material to produce polymers of amino acids depends 
majorly on 1) accurate tRNA aminoacylation and 2) precise deciphering of codons and 
appropriate translocation of tRNA after the peptide bond formation [82].  
To recognize the complete functional potential of diverse amino acids and unravel the 
shortcomings that restrict the development of protein applications, expansion of the genetic code 
becomes necessary. The ability to engineer and rewire the genetic code to expand the repertoire 
of amino acids with novel physical and chemical properties opens a new avenue in synthetic 
protein chemistry. With increasing interest to develop designer proteins, underpinning the 
translation machinery requires 3 conditions: 1) an orthogonal aaRS/tRNA pair 2) specificity of 
aminoacyl–tRNA synthetase (aaRS) to an unnatural amino acid and 3) a blank codon (Figure 
1.6). Development of orthogonal translational systems (OTS) introduce the possibilities for 
synthesis of biopolymers and materials, other than just L-α-AA configuration, with applications 
for immunotherapy, therapeutic peptides, vaccines, etc. [83]. 
 
1.3.1 Orthogonal translational systems (OTS) 
To develop an evolved orthogonal aaRS-tRNA pair, scientists acquire the system from 
other domains of life such as archaea. For instance, TyrRS-tRNA pair from Methanocaldococcus 
jannaschii is used in E. coli and other bacteria [84], LeuRS-tRNA pair from E. coli has been 
used in eukaryotes [85], and a pyrrolysyl-aaRS-tRNA pair (PylRS-tRNACUA) developed from 
mutations of Methanosarcina mazei is adaptable in both E. coli and eukaryotes [86, 87].  
The term orthogonality here signifies that the donor tRNA does not serve as a substrate 
for endogenous synthetases in the host but is exclusively aminoacylated only by the orthogonal 
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synthetase. The subtle divergence between the orthogonal aaRS-tRNA pairs of the donor 
organism and the host help maintain the required orthogonality. This prevents the cross reactivity 
of the aaRS-tRNA pair between the organisms [88]. Each ncAA is incorporated in reciprocation 
to the non-sense or stop codon at the site of interest. The most successful incorporation happens 
when the non-canonical amino acid (ncAA) resembles or mimics a natural amino acid. So far, 
pyrrolysyl-tRNA synthetase (PylRS) is the most proficient aaRS for incorporating ncAAs [89, 
90] in both prokaryotes and eukaryotes.  
 
1.3.2 Selection of Aminoacyl tRNA synthetases 
Selection of a compatible aaRS is crucial and through the required evolution aaRS is 
made suitable for the incorporation of ncAA. Conventionally, a large variant library 
(approximately 109 variants) consisting of mutations in the active site of the synthetase is created 
as the first step. E. coli with the synthetase library and cognate tRNA are cultured with amber 
codons at permissible sites and selection is based on positive antibiotic resistance such as 
ampicillin, or chloramphenicol. 
 
Figure 1.7 Evolution of aaRS variants developed using MAGE. E. coli is recoded to contain a 
chromosomal copy of aaRS for evolution. Negative selection markers and green fluorescence 
protein (GFP) are used for screening the variants. In this case, tolC and colicin are used for 
negative selection. The selected aaRS variants are assessed for ncAA incorporation at multiple 
sites [91]. 
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In the second step, negative barnase selection is employed. The selected clones showing 
antibiotic resistance are transformed with the barnase gene, which on expression is toxic to cells. 
Thus in the absence of ncAA in media, clones that incorporate natural amino acids are 
annihilated and only the ones which use ncAA survive [92]. 
To increase efficiency and improve the specificity of aaRS to a variety of ncAAs 
multiplex automated genome engineering (MAGE) was used (Figure 1.7). This technique 
chromosomally integrates aaRS in organisms comprising positive and negative selection to 
generate libraries. Using MAGE, M. jannaschii TyrRS was developed to leverage up to 12 
mutational changes in the active site and anticodon binding sides and also prevented gene 
expression fluctuations associated with plasmids. Results showed that after the first selection 
process and two cell sorting cycles, incorporation of ncAAs at 30 sites of the reporter protein 
with approximately 50 mg/L yield was produced. The fidelity of the mutant was more than 95% 
for each ncAA at the UAG incorporation sites [91]. 
Other powerful technologies used to evolve aaRS are Phage-assisted continuous 
evolution (PACE) and phage-assisted noncontinuous evolution (PANCE), which utilize 
bacteriophage propagation technique [93].  
In PACE, random libraries of plasmid mutations are created with a defined mutational 
frequency (Figure 1.8). By generating many rounds of evolution, aaRS that are many folds active 
and selective are obtained. Combining the mutation and selection cycles, this process evolved 
Methanosarcina spp. pyrrolysyl-tRNA synthetase (PylRS) that showed 45 folds improved 
enzymatic competence than the wildtype, thereby leading to 9.7 increased yields of protein 
containing ncAA [94].  
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Figure 1.8 Representation of PACE. Accessory plasmid (AP) and complementary plasmid 
(CP) encode for the cognate tRNA and T7 RNAP, respectively. The mutagenesis plasmid (MP) 
multiples the rate of evolution through arabinose induction and SP represents the selection phage 
[94].  
To evolve PylRS further with enhanced selectivity of ncAAs, PANCE was developed. 
For an active in vivo focused evolution of aaRS, a simple and accessible use of serial flasks 
transfer of the evolving selection phage’ (SP) with the gene of interest was employed. As E. coli 
was used as a host cell, the genes in the bacteria were held stable, while the genes in SP were 
subjected to continuous evolution [95].  
Recently, efforts to expand the diversity of PylRS have been explored by studying 
interactions apart from the active site. By examining the remote interactions between tRNAPyl, 
the tRNA binding domain of PylRS, it has been found that the flexible loop region of the PylRS 
that links the N-terminal and C-terminal domains plays a crucial role in binding regulations. 
Therefore, varying lengths of linkers were tested to expand amber suppression efficiencies and 
substrate specificity. It was learned that linkers of moderate length modify the PylRS and 
tRNAPyl binding and consequently improves the output [96].  
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1.3.3 Engineering tRNA 
tRNAs are key molecules that are a crucial part of the dynamics of protein translation. 
Efficiency of tRNAs to deliver amino acids to ribosomes depend on various factors such as 
expression, maturation, structure, and stability. Subsequently, modifications of tRNA are 
required to produce ncAA in synthetic biology. Determinants which aid in interactions between 
tRNA and aaRS, and binding of elongation factors, and ncAAs will be considered for genetic 
code expansion. Mutations are also sometimes made to avoid binding to non-cognate aaRS [97] 
or to impose identity to prevent erroneous charging [98].  
As stop codons are commonly used to incorporate ncAAs into designer proteins, tRNAs 
used in genetic code expansion are the ones with no identity elements in the anticodon region. 
This will help making mutations to the anticodon arm in order to recognize the stop codons used. 
Biosynthesis of such tRNAs are carried out using E. coli as a model organism. To match the 
tRNA sequences in different forms of life, modifications are made accordingly. For example, for 
ncAA expression in bacteria, CCA terminal sequence is added to the 3’ end of the tRNA gene 
from archaea. Such alterations become mandatory to help expression and recognition in the host 
organism [89]. Some expressed tRNAs undergo post-translational modifications [99] and in case 
of anomalous tRNA synthesis, they are digested by nucleases present in the cell [100] [101, 102]. 
 
1.3.4 OTS in E. coli  
For cotranslation of ncAA into proteins, E. coli is the most commonly used organism as it 
has a well-studied translational system that is efficient and simple. In most cases stop codons 
UAG, UGA, and UAA codons serve as a blank for the addition of ncAA [103]. Stop codons 
UAG and UAA are recognized by the Release Factor 1 (RF1) in prokaryotes, while RF2 
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recognizes UAA and UGA [104]. Commonly, UAG amber codon is used because of its minimal 
occurrence in most organisms when compared to other codons. An evolved orthogonal ribosome 
with mutations in the 16S rRNA was developed to function parallelly with the natural ribosome 
in the cell [105]. Another approach to enhance the translational system was to replace the 
essential genes that have an amber codon with UAA.  
 
1.3.5 Applications of genetic code expansion 
Genetic code expansion has been commonly used to analyze structure and function of 
different proteins, both in vitro and in vivo. To achieve this, chemical cross linkers and 
fluorescent ncAAs’ are used. This technique can also be used as a powerful tool to improve 
pharmacological properties of proteins used in therapeutic applications. Antibodies with 
improved potency, pharmacokinetics, and safety were synthesized by incorporating p-
acetylphenylalanine (pAcF) genetically on anti-Her2 antibody and similar methods were 
implemented for other antibodies production such as bispecific antibodies or antibodies used in 
radioimmunotherapy. The applications of genetic code expansion expanded further for the 
synthesis of therapeutic peptides, modified viruses, and therapeutic vaccines [83].  
To study lysine acetylation, many genetic code expansion systems have been developed 
including the AcK system that was engineered from PylRS. This system has 10-fold increase in 
the incorporation efficiency. Our group further optimized the AcK incorporation protocol by 
linking AcKRS variant and tRNAPyl for improved amber readthrough up to 70%. Moreover, to 
evade the action of deacetylases for various studies, non-deacetylatable AcK analogs have been 
used. These include 2-amino-8-oxononanoic acid (KetoK), thio-acetyllysine (TAcK), and 
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trifluoro-acetyllysine (TFAcK). Apart from histones, acetylation was also studied in p53, human 
peroxiredoxin 1 (hPrX1), GTP-binding protein Ran, and E. coli TyrRS [61]. 
 
1.4 Rationale and gap in knowledge 
Protein acetylation plays a substantial role in almost all biological processes. The 
abnormalities in acetylation patterns can cause diseases such as diabetes, cardiovascular diseases, 
cancers, and neurodegenerative disorders. In the recent years, proteomic studies have recognized 
the role of lysine acetylation in thousands of eukaryotic proteins which significantly expanded 
our knowledge, but the characterization of TCA cycle enzymes in relation to acetylation has not 
yet been fully studied. In this project, we aim to understand the role of acetylation on the 
enzymes of the TCA cycle and how such modifications could lead to the alterations of enzyme 
activity. Regulation of enzyme activities has a huge role to play in either maintaining or 
disrupting the homeostasis of the body. Thus, these results could lay the foundation for 
understanding the development of different diseases such as cancer and could help advance the 
search for its treatment. 
 
 
 
 
 
 
 
 
29 
1.5 References 
1. Garrett H. Reginald and Charles Grisham. Biochemistry Boston: Twayne Publishers. 2008. 
2. Nunes-Nesi A, Araújo WL, Obata T, Fernie AR. Regulation of the mitochondrial tricarboxylic 
acid cycle. Current opinion in plant biology. 2013;16:335-43. 
3. Lieberman M, Marks AD. Marks' basic medical biochemistry: a clinical approach: Lippincott 
Williams & Wilkins; 2009. 
4. Zhang Y, Swart C, Alseekh S, Scossa F, Jiang L, Obata T, et al. The extra-pathway interactome 
of the TCA cycle: expected and unexpected metabolic interactions. Plant physiology. 
2018;177:966-79. 
5. Aoshima M. Novel enzyme reactions related to the tricarboxylic acid cycle: 
phylogenetic/functional implications and biotechnological applications. Applied microbiology and 
biotechnology. 2007;75:249-55. 
6. Christos C. Which way does the citric acid cycle turn during hypoxia? The critical role of alpha-
ketoglutarate dehydrogenase complex. 2013. 
7. Akram M. Citric acid cycle and role of its intermediates in metabolism. Cell biochemistry and 
biophysics. 2014;68:475-8. 
8. Morowitz HJ. Yale University Press; New Haven, CT: 1992. Beginnings of cellular life: 
metabolism recapitulates biogenesis[Google Scholar]. 
9. Greenwood NN, Earnshaw A. Chemistry of the Elements: Elsevier; 2012. 
10. Maltais TR, VanderVelde D, LaRowe DE, Goldman AD, Barge LM. Reactivity of Metabolic 
Intermediates and Cofactor Stability under Model Early Earth Conditions. Origins of Life and 
Evolution of Biospheres. 2020;50:35-55. 
11. Smith E, Morowitz HJ. Universality in intermediary metabolism. Proceedings of the National 
Academy of Sciences. 2004;101:13168-73. 
12. Springsteen G, Yerabolu JR, Nelson J, Rhea CJ, Krishnamurthy R. Linked cycles of oxidative 
decarboxylation of glyoxylate as protometabolic analogs of the citric acid cycle. Nature 
communications. 2018;9:1-8. 
13. Kwong WK, Zheng H, Moran NA. Convergent evolution of a modified, acetate-driven TCA 
cycle in bacteria. Nature microbiology. 2017;2:1-3. 
14. Becerra A, Rivas M, García-Ferris C, Lazcano A, Peretó J. A phylogenetic approach to the 
early evolution of autotrophy: the case of the reverse TCA and the reductive acetyl-CoA pathways. 
Int Microbiol. 2014;17:91-7. 
 
30 
15. Hards K, Adolph C, Harold LK, McNeil MB, Cheung C-Y, Jinich A, et al. Two for the price 
of one: Attacking the energetic-metabolic hub of mycobacteria to produce new chemotherapeutic 
agents. Progress in biophysics and molecular biology. 2020;152:35-44. 
16. Baughn AD, Garforth SJ, Vilchèze C, Jacobs Jr WR. An anaerobic-type α-ketoglutarate 
ferredoxin oxidoreductase completes the oxidative tricarboxylic acid cycle of Mycobacterium 
tuberculosis. PLoS Pathog. 2009;5:e1000662. 
17. Plaitakis A, Kalef-Ezra E, Kotzamani D, Zaganas I, Spanaki C. The glutamate dehydrogenase 
pathway and its roles in cell and tissue biology in health and disease. Biology. 2017;6:11. 
18. Berg JM, Tymoczko JL, Stryer L. The biosynthesis of amino acids. Biochemistry New York: 
WH Freeman. 2002:665-92. 
19. D'Mello JPF. Amino acids in animal nutrition: CABI publishing; 2003. 
20. Nelson DL, Lehninger AL, Cox MM. Lehninger principles of biochemistry: Macmillan; 2008. 
21. Gibson KD, Laver WG, Neuberger A. Initial stages in the biosynthesis of porphyrins. 2. The 
formation of δ-aminolaevulic acid from glycine and succinyl-coenzyme A by particles from 
chicken erythrocytes. Biochemical Journal. 1958;70:71-81. 
22. Burch JS, Marcero JR, Maschek JA, Cox JE, Jackson LK, Medlock AE, et al. Glutamine via 
α-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. 
blood. 2018;132:987-98. 
23. Angajala A, Lim S, Phillips JB, Kim J-H, Yates C, You Z, et al. Diverse roles of mitochondria 
in immune responses: novel insights into immuno-metabolism. Frontiers in immunology. 
2018;9:1605. 
24. Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The metabolic signature of 
macrophage responses. Frontiers in immunology. 2019;10. 
25. Noe JT, Mitchell RA. Tricarboxylic acid cycle metabolites in the control of macrophage 
activation and effector phenotypes. Journal of leukocyte biology. 2019;106:359-67. 
26. Patil NK, Bohannon JK, Hernandez A, Patil TK, Sherwood ER. Regulation of leukocyte 
function by citric acid cycle intermediates. Journal of leukocyte biology. 2019;106:105-17. 
27. Hasanpour M, Iranshahy M, Iranshahi M. The application of metabolomics in investigating 
anti-diabetic activity of medicinal plants. Biomedicine & Pharmacotherapy. 2020;128:110263. 
28. Huang L, Wang C, Xu H, Peng G. Targeting citrate as a novel therapeutic strategy in cancer 
treatment. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020;1873:188332. 
29. Tian X, Zhang K, Min J, Chen C, Cao Y, Ding C, et al. Metabolomic analysis of influenza A 
virus A/WSN/1933 (H1N1) infected A549 cells during first cycle of viral replication. Viruses. 
2019;11:1007. 
 
31 
30. Rydström J. Mitochondrial NADPH, transhydrogenase and disease. Biochimica et Biophysica 
Acta (BBA)-Bioenergetics. 2006;1757:721-6. 
31. Sies H, Berndt C, Jones DP. Oxidative stress. Annual review of biochemistry. 2017;86:715-
48. 
32. Gansemer ER, McCommis KS, Martino M, King-McAlpin AQ, Potthoff MJ, Finck BN, et al. 
NADPH and glutathione redox link TCA cycle activity to endoplasmic reticulum homeostasis. 
Iscience. 2020:101116. 
33. Marquez J, Flores J, Kim AH, Nyamaa B, Nguyen ATT, Park N, et al. Rescue of TCA Cycle 
Dysfunction for Cancer Therapy. Journal of Clinical Medicine. 2019;8:2161. 
34. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA 
cycle in cancer metabolism. Protein & cell. 2018;9:216-37. 
35. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. 
Trends in molecular medicine. 2011;17:641-9. 
36. Kreitz J, Schönfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, et al. Metabolic plasticity 
of acute myeloid leukemia. Cells. 2019;8:805. 
37. Shan M, Dai D, Vudem A, Varner JD, Stroock AD. Multi-scale computational study of the 
Warburg effect, reverse Warburg effect and glutamine addiction in solid tumors. PLoS 
computational biology. 2018;14:e1006584. 
38. Todisco S, Convertini P, Iacobazzi V, Infantino V. TCA Cycle Rewiring as Emerging 
Metabolic Signature of Hepatocellular Carcinoma. Cancers. 2020;12:68. 
39. Montégut L, Martínez-Basilio PC, da Veiga Moreira J, Schwartz L, Jolicoeur M. Combining 
lipoic acid to methylene blue reduces the Warburg effect in CHO cells: From TCA cycle activation 
to enhancing monoclonal antibody production. Plos one. 2020;15:e0231770. 
40. Musrati RA, Kollarova M, Mernik N, Mikulasova D. Malate dehydrogenase: distribution, 
function and properties. General physiology and biophysics. 1998;17:193-210. 
41. Dasika SK, Vinnakota KC, Beard DA. Determination of the catalytic mechanism for 
mitochondrial malate dehydrogenase. Biophysical journal. 2015;108:408-19. 
42. Minarik P, Tomaskova N, Kollarova M, Antalik M. Malate dehydrogenases-structure and 
function. General physiology and biophysics. 2002;21:257-66. 
43. Naik R, Ban HS, Jang K, Kim I, Xu X, Harmalkar D, et al. Methyl 3-(3-(4-(2, 4, 4-
Trimethylpentan-2-yl) phenoxy)-propanamido) benzoate as a novel and dual malate 
dehydrogenase (MDH) 1/2 inhibitor targeting cancer metabolism. Journal of Medicinal Chemistry. 
2017;60:8631-46. 
 
32 
44. New M, Van Acker T, Sakamaki J-I, Jiang M, Saunders RE, Long J, et al. MDH1 and MPP7 
regulate autophagy in pancreatic ductal adenocarcinoma. Cancer research. 2019;79:1884-98. 
45. Schmitz M, Llorens F, Pracht A, Thom T, Correia Â, Zafar S, et al. Regulation of human 
cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients. Aging 
(Albany NY). 2016;8:2927. 
46. Broeks MH, Shamseldin HE, Alhashem A, Hashem M, Abdulwahab F, Alshedi T, et al. MDH1 
deficiency is a metabolic disorder of the malate–aspartate shuttle associated with early onset severe 
encephalopathy. Human genetics. 2019;138:1247-57. 
47. Ait-El-Mkadem S, Dayem-Quere M, Gusic M, Chaussenot A, Bannwarth S, François B, et al. 
Mutations in MDH2, encoding a Krebs cycle enzyme, cause early-onset severe encephalopathy. 
The American Journal of Human Genetics. 2017;100:151-9. 
48. Wang XM, Soetaert K, Peirs P, Kalai M, Fontaine V, Dehaye JP, et al. Biochemical analysis 
of the NAD+-dependent malate dehydrogenase, a substrate of several serine/threonine protein 
kinases of Mycobacterium tuberculosis. PLoS One. 2015;10:e0123327. 
49. Kim WS, Kim J-S, Shin M-K, Shin SJ. A novel Th1-type T-cell immunity-biasing effect of 
malate dehydrogenase derived from Mycobacterium avium subspecies paratuberculosis via the 
activation of dendritic cells. Cytokine. 2018;104:14-22. 
50. Han X, Tong Y, Tian M, Sun X, Wang S, Ding C, et al. Characterization of the immunogenicity 
and pathogenicity of malate dehydrogenase in Brucella abortus. World Journal of Microbiology 
and Biotechnology. 2014;30:2063-70. 
51. Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular 
insight. Cell & bioscience. 2017;7:37. 
52. Trembath DG. Molecular Testing for Glioblastoma.  Diagnostic Molecular Pathology: 
Elsevier; 2017. p. 339-47. 
53. Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase 
(IDH) in cancer. Discovery medicine. 2016;21:373-80. 
54. Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in 
cancer. Cancer Cell. 2018;34:186-95. 
55. Murray SL, Hynes MJ. Metabolic and developmental effects resulting from deletion of the 
citA gene encoding citrate synthase in Aspergillus nidulans. Eukaryotic Cell. 2010;9:656-66. 
56. Cai Q, Zhao M, Liu X, Wang X, Nie Y, Li P, et al. Reduced expression of citrate synthase 
leads to excessive superoxide formation and cell apoptosis. Biochemical and biophysical research 
communications. 2017;485:388-94. 
 
33 
57. Vornhagen J, Sun Y, Breen P, Forsyth V, Zhao L, Mobley HLT, et al. The Klebsiella 
pneumoniae citrate synthase gene, gltA, influences site specific fitness during infection. PLoS 
pathogens. 2019;15:e1008010. 
58. Wang N, Zhu H, Zhan J, Guo C, Shen N, Gu X, et al. Cloning, expression, characterization, 
and immunological properties of citrate synthase from Echinococcus granulosus. Parasitology 
research. 2019;118:1811-20. 
59. Ullian ME, Gantt BJ, Ford AK, Tholanikunnel BG, Spicer EK, Fitzgibbon WR. Potential 
importance of glomerular citrate synthase activity in remnant nephropathy. Kidney international. 
2003;63:156-64. 
60. Lin C-C, Cheng T-L, Tsai W-H, Tsai H-J, Hu K-H, Chang H-C, et al. Loss of the respiratory 
enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Scientific reports. 
2012;2:785. 
61. Chen H, Venkat S, McGuire P, Gan Q, Fan C. Recent Development of Genetic Code Expansion 
for Posttranslational Modification Studies. Molecules. 2018;23:1662. 
62. Kontaxi C, Piccardo P, Gill AC. Lysine-directed post-translational modifications of tau protein 
in Alzheimer's disease and related Tauopathies. Frontiers in molecular biosciences. 2017;4:56. 
63. Schaffert L-N, Carter WG. Do Post-Translational Modifications Influence Protein Aggregation 
in Neurodegenerative Diseases: A Systematic Review. Brain Sciences. 2020;10:232. 
64. Nakamura T, Lipton SA. Nitric Oxide-Dependent Protein Post-Translational Modifications 
Impair Mitochondrial Function and Metabolism to Contribute to Neurodegenerative Diseases. 
Antioxidants & Redox Signaling. 2020;32:817-33. 
65. Tomin T, Schittmayer M, Honeder S, Heininger C, Birner-Gruenberger R. Irreversible 
oxidative post-translational modifications in heart disease. Expert review of proteomics. 
2019;16:681-93. 
66. Rodríguez-Paredes M, Lyko F. The importance of non-histone protein methylation in cancer 
therapy. Nature Reviews Molecular Cell Biology. 2019:1-2. 
67. Yan F, Qian M, He Q, Zhu H, Yang B. The posttranslational modifications of Hippo-YAP 
pathway in cancer. Biochimica et Biophysica Acta (BBA)-General Subjects. 2020;1864:129397. 
68. Santos AL, Lindner AB. Protein posttranslational modifications: roles in aging and age-related 
disease. Oxidative Medicine and Cellular Longevity. 2017;2017. 
69. Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone 
methylation in ageing and cancer. Nature Reviews Molecular Cell Biology. 2019:1. 
70. Ribet D, Cossart P. Post-translational modifications in host cells during bacterial infection. 
FEBS letters. 2010;584:2748-58. 
 
34 
71. Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. Biochimica et 
Biophysica Acta (BBA)-Proteins and Proteomics. 2016;1864:1372-401. 
72. Christensen DG, Xie X, Basisty N, Byrnes J, McSweeney S, Schilling B, et al. Post-
translational protein acetylation: an elegant mechanism for bacteria to dynamically regulate 
metabolic functions. Frontiers in microbiology. 2019;10:1604. 
73. Sadowska-Bartosz I, Bartosz G, Grune T, Sereikaite J. Role of Oxidative, Nitrative, and 
Chlorinative Protein Modifications in Aging and Age-Related Diseases. Oxidative medicine and 
cellular longevity. 2018;2018. 
74. Hofweber M, Dormann D. Friend or foe—Post-translational modifications as regulators of 
phase separation and RNP granule dynamics. Journal of Biological Chemistry. 2019;294:7137-50. 
75 Grimes M, Hall B, Foltz L, Levy T, Rikova K, Gaiser J, et al. Integration of protein 
phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks. 
Science signaling. 2018;11:eaaq1087. 
76. Wang Y-C, Peterson SE, Loring JF. Protein post-translational modifications and regulation of 
pluripotency in human stem cells. Cell research. 2014;24:143-60. 
77. Min S-W, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-
mediated neurodegeneration and cognitive deficits. Nature medicine. 2015;21:1154-62. 
78. Thomas EA. Histone posttranslational modifications in schizophrenia.  Neuroepigenomics in 
aging and disease: Springer; 2017. p. 237-54. 
79. Gil J, Ramírez-Torres A, Encarnación-Guevara S. Lysine acetylation and cancer: A proteomics 
perspective. Journal of proteomics. 2017;150:297-309. 
80. Wang Y, Yuan Q, Xie L. Histone modifications in aging: the underlying mechanisms and 
implications. Current stem cell research & therapy. 2018;13:125-35. 
81. Venkat S, Chen H, Gan Q, Fan C. The Application of Cell-free Protein Synthesis in Genetic 
Code Expansion for Post-translational Modifications. Frontiers in Pharmacology. 2019;10:248. 
82. Chin JW. Reprogramming the genetic code. The EMBO journal. 2011;30:2312-24. 
83. Huang Y, Liu T. Therapeutic applications of genetic code expansion. Synthetic and Systems 
Biotechnology. 2018. 
84. Wang L, Brock A, Herberich B, Schultz PG. Expanding the genetic code of Escherichia coli. 
Science. 2001;292:498-500. 
85. Wu N, Deiters A, Cropp TA, King D, Schultz PG. A genetically encoded photocaged amino 
acid. Journal of the American Chemical Society. 2004;126:14306-7. 
 
35 
86. Kobayashi T, Yanagisawa T, Sakamoto K, Yokoyama S. Recognition of non-α-amino 
substrates by pyrrolysyl-tRNA synthetase. Journal of molecular biology. 2009;385:1352-60. 
87. Mukai T, Kobayashi T, Hino N, Yanagisawa T, Sakamoto K, Yokoyama S. Adding l-lysine 
derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. 
Biochemical and biophysical research communications. 2008;371:818-22. 
88. Melnikov SV, Söll D. Aminoacyl-tRNA Synthetases and tRNAs for an Expanded Genetic 
Code: What Makes them Orthogonal? International Journal of Molecular Sciences. 2019;20:1929. 
89. Hoffman KS, Crnković A, Söll D. Versatility of synthetic tRNAs in genetic code expansion. 
Genes. 2018;9:537. 
90. Crnković A, Suzuki T, Söll D, Reynolds NM. Pyrrolysyl-tRNA synthetase, an aminoacyl-
tRNA synthetase for genetic code expansion. Croatica chemica acta Arhiv za kemiju. 2016;89:163. 
91. Amiram M, Haimovich AD, Fan C, Wang Y-S, Aerni H-R, Ntai I, et al. Evolution of translation 
machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids. Nature 
biotechnology. 2015;33:1272-9. 
92. Wang L, Schultz PG. A general approach for the generation of orthogonal tRNAs. Chemistry 
& biology. 2001;8:883-90. 
93. Vargas-Rodriguez O, Sevostyanova A, Söll D, Crnković A. Upgrading aminoacyl-tRNA 
synthetases for genetic code expansion. Current opinion in chemical biology. 2018;46:115-22. 
94. Bryson DI, Fan C, Guo L-T, Miller C, Söll D, Liu DR. Continuous directed evolution of 
aminoacyl-tRNA synthetases. Nature chemical biology. 2017;13:1253-60. 
95. Suzuki T, Miller C, Guo L-T, Ho JML, Bryson DI, Wang Y-S, et al. Crystal structures reveal 
an elusive functional domain of pyrrolysyl-tRNA synthetase. Nature chemical biology. 
2017;13:1261-6. 
96. Jiang H-K, Lee M-N, Tsou J-C, Chang K-W, Tseng H-W, Chen K-P, et al. Linker and N-
terminal domain engineering of pyrrolysyl-tRNA synthetase for substrate range shifting and 
activity enhancement. Frontiers in bioengineering and biotechnology. 2020;8. 
97. Auld DS, Schimmel P. Switching recognition of two tRNA synthetases with an amino acid 
swap in a designed peptide. Science. 1995;267:1994-6. 
98. Perret V, Garcia A, Grosjean H, Ebel J-P, Florentz C, Giegé R. Relaxation of a transfer RNA 
specificity by removal of modified nucleotides. Nature. 1990;344:787-9. 
99. Machnicka MA, Olchowik A, Grosjean H, Bujnicki JM. Distribution and frequencies of post-
transcriptional modifications in tRNAs. RNA biology. 2014;11:1619-29. 
 
36 
100. Kadaba S, Wang X, Anderson JT. Nuclear RNA surveillance in Saccharomyces cerevisiae: 
Trf4p-dependent polyadenylation of nascent hypomethylated tRNA and an aberrant form of 5S 
rRNA. Rna. 2006;12:508-21. 
101. Kadaba S, Krueger A, Trice T, Krecic AM, Hinnebusch AG, Anderson J. Nuclear surveillance 
and degradation of hypomodified initiator tRNAMet in S. cerevisiae. Genes & development. 
2004;18:1227-40. 
102. Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, et al. Rapid tRNA 
decay can result from lack of nonessential modifications. Molecular cell. 2006;21:87-96. 
103. Chin JW. Expanding and reprogramming the genetic code of cells and animals. Annual 
review of biochemistry. 2014;83:379-408. 
104. Arranz-Gibert P, Vanderschuren K, Isaacs FJ. Next-generation genetic code expansion. 
Current opinion in chemical biology. 2018;46:203-11. 
105. Rackham O, Chin JW. A network of orthogonal ribosome· mRNA pairs. Nature chemical 
biology. 2005;1:159-66. 
 
  
 
37 
CHAPTER II 
STUDYING THE LYSINE ACETYLATION OF MALATE DEHYDROGENASE  
Sumana Venkata,b, Caroline Gregoryc, Jourdan Sturgesc, Qinglei Gana, and Chenguang Fana,b 
aDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR, 72701  
bCell and Molecular Biology Program, University of Arkansas, Fayetteville, AR, 72701  
cDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR, 72701 
 
2.1 Abstract  
Protein acetylation plays important roles in many biological processes. Malate 
dehydrogenase (MDH), a key enzyme in the tricarboxylic acid (TCA) cycle, has been identified 
to be acetylated in bacteria by proteomic studies, but no further characterization has been 
reported. One challenge for studying protein acetylation is to get purely acetylated proteins at 
specific positions. Here we applied the genetic code expansion strategy to site-specifically 
incorporate Nε -acetyllysine into MDH. The acetylation of lysine residues in MDH could 
enhance its enzyme activity. The Escherichia coli deacetylase CobB could deacetylate acetylated 
MDH, while the E. coli acetyltransferase YfiQ cannot acetylate MDH efficiently. Our results 
also demonstrated that acetyl CoA or acetyl-phosphate could acetylate MDH chemically in vitro. 
Furthermore, the acetylation level of MDH was shown to be affected by carbon sources in the 
growth medium. 
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2.2 Introduction 
The acetylation of lysine residues is one of the most common post-translational 
modifications of proteins that regulates diverse cellular functions including DNA-protein 
interaction, transcription activity, protein stability, stress response, apoptosis, cellular 
differentiation, and energy metabolism [1–13]. The abnormality of acetylation modifications is 
associated with diabetes, cardiovascular diseases, cancers, and neurodegenerative disorders [14–
24]. During the last decade, proteomic studies have identified lysine acetylation in thousands of 
eukaryotic proteins which significantly expanded our knowledge of protein acetylation [25–27]. 
Interestingly, protein acetylation in bacteria starts to attract attentions in the last five 
years [28–35]. A series of proteomic studies have identified hundreds of bacterial proteins with 
lysine acetylation, including metabolic enzymes, stress response proteins, regulator of 
chemotaxis, chaperones, as well as transcription and translation factors [36–47]. However, few 
studies have been performed to further characterize these acetylated proteins. Take E. coli as an 
example, only six proteins with lysine acetylation were studied, including acetyl CoA synthetase 
[48–51]; CheY, the regulator of bacterial chemotaxis [52–54]; RcsB, the regulator of capsule 
synthesis [55–57]; RNase R [58], N-hydroxyarylamine O-acetyltransferase [59], and α-subunit of 
RNA polymerase [60, 61]. One challenge for studying lysine acetylation is that it is difficult to 
synthesize purely acetylated proteins at specific sites by most classic methods. To solve this 
problem, the genetic code expansion strategy has been applied. Rather than adding acetyl group 
after protein translation, this approach uses an orthogonal pair of an engineered pyrrolysyl-tRNA 
synthetase variant and its cognate tRNA from Methanosarcinaceae species to co-translationally 
direct the incorporation of Nε -acetyllysine (AcK) in response to a stop codon at desired positions 
in target proteins [62–65].  
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MDH, a widely distributed enzyme catalyzing the conversion of oxaloacetate and malate, 
plays key roles in many important metabolic pathways including the tricarboxylic acid (TCA) 
cycle, glyoxylate bypass, amino acid synthesis, gluconeogenesis, and the exchange of 
metabolites between cytoplasm and subcellular organelles [66, 67]. Previous studies have shown 
that the acetylation of lysine residues in mammalian MDHs is involved in the crosstalk 
mechanisms between adipogenesis and the intracellular energy level [68–70]. However, the 
acetylation of bacterial MDH has not been characterized before. Here, we applied the genetic 
code expansion strategy to study the lysine acetylation of MDH in E. coli. We also used the same 
strategy to study human MDH as comparison. 
 
2.3 Materials and Methods 
2.3.1 General molecular biology  
The amino acids in this study were purchased from Sigma-Aldrich or ChemImpex. 
TOP10 cells (Life Technologies) were used for general cloning. All the cloning experiments 
were performed by using the Gibson Assembly kit (New England Biolabs). The mutations of 
stop codons in MDH genes were made by the QuikChange II mutagenesis kit (Agilent 
Technologies). The strains and plasmids used in this study is listed in Table S1. Western Blots: 
The purified MDHs and their variants were fractionated by SDS-PAGE and transferred onto a 
PVDF membrane (Bio-Rad). The membrane was incubated at room temperature with gentle 
shacking in TTBS and 5% Milk blocking buffer for 60 minutes. The primary antibody, HRP-
conjugated-Acetylated-Lysine (Ac-K2 -100) Rabbit mAb (Cell Signaling Technology), was 
diluted 1:1000 and soaked the membranes overnight at 4℃ degree. The membrane was prepared 
for detection using Western Lighting Plus-ECL (PerkinElmer, Inc.). The E. coli proteins 
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including CobB and 25 GNAT family acetyltransferases were purified from the ASKA strain 
collection by following the purification protocols [97]. The human SIRT3 was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The gene deletion in E. coli was performed by 
recombination as previous protocols [98].  
 
2.3.2 Expression and purification of AcK-containing MDH variants 
The genes of MDHs and their variants were cloned into the pET15b or pBAD plasmid 
with a C-terminal His6-tag and transformed into BL21 (DE3) or Top 10 cells together with the 
pTech plasmids harboring the AcK incorporation system for expression. For human MDH2 
expression, the predicted mitochondrial targeting sequence (residues 2–24) was removed. The 
expression strain was grown on 1 L of LB medium supplemented with 100 μg/mL ampicillin and 
50 μg/mL chloramphenicol at 37°C to an absorbance of 0.6–0.8 at 600 nm and protein 
expression was induced by the addition of 1 mM IPTG and supplemented with 5 mM AcK and 
20 mM nicotinamine (NAM, deacetylases inhibitor). Cells were incubated at 30°C for an 
additional 8 h and harvested by centrifugation at 5000 × g for 10 min at 4°C. The cell paste was 
suspended in 15 mL of lysis buffer (50 mM Tris (pH 7.5), 300 mM NaCl, 20 mM imidazole, 20 
mM NAM) and broken by sonication. The crude extract was centrifuged at 20,000 × g for 30 
minutes at 4°C. The soluble fraction was loaded onto a column containing 2 mL of Ni-NTA resin 
(Qiagen) previously equilibrated with 20 mL lysis buffer. The column was washed with 50 mL 
lysis buffer. The protein bound to the column was then eluted with 2 mL of 50 mM Tris (pH 
7.5), 300 mM NaCl, 150 mM imidazole. The purified protein was dialyzed with 50 mM Tris (pH 
7.5), 50 mM NaCl, 1mM DTT and 50% glycerol, and stored at −80°C for further studies.  
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2.3.3 MDH enzyme assays  
The assays were performed by following the instruction of the EnzyChromTM Malate 
Dehydrogenase Assay Kit (EMDH-100) from BioAssay Systems. This non-radioactive, 
colorimetric MDH assay is based on the reduction of the tetrazolium salt MTT in a NADH-
coupled enzymatic reaction to a reduced form of MTT which exhibits an absorption maximum at 
565 nm. The increase in absorbance at 565 nm is proportional to the enzyme activity. 
 
2.3.4 LC-MS/MS analyses 
The proteins were trypsin digested by a standard in-gel digestion protocol and analyzed 
by LC-MS/MS on an LTQ Orbitrap XL (Thermo Scientific) equipped with a nanoACQUITY 
UPLC system (Waters). A Symmetry C18 trap column (180 μm × 20 mm; Waters) and a 
nanoACQUITY UPLC column (1.7 μm, 100 μm × 250 mm, 35°C) were used for peptide 
separation. Trapping was done at 15 μL min−1, 99% buffer A (water with 0.1% formic acid) for 1 
min. Peptide separation was performed at 300 nL min−1 with buffer A and buffer B (CH3CN 
containing 0.1% formic acid). The linear gradient (51 min) was from 5% buffer B to 50% B at 50 
min, to 85% B at 51 min. MS data were acquired in the Orbitrap with one microscan, and a 
maximum inject time of 900 ms followed by data-dependent MS/MS acquisitions in the ion trap 
(through collision induced dissociation, CID). The Mascot search algorithm was used to search 
for the appropriate noncanonical substitution (Matrix Science, Boston, MA).  
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2.3.5 In vitro acetylation  
The reaction was performed in the buffer containing 50 mM Tris-HCl (pH 8.0), 0.1 mM 
EDTA, 10% glycerol, 1 mM DTT and 10 mM sodium butyrate. The acetylation was carried out 
by adding 10 μg MDHs, 10 μg of candidate acetyltransferase, and 0.2 mM acetyl CoA in a 
volume of 100 μL. Reaction mixtures were completely mixed and incubated at 37 °C.  
 
2.3.6 CobB-mediated in vitro deacetylation  
The reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM MgCl2, 
1.0 mM NAD+, 1 mM DTT and 10 % glycerol. 10 μg MDHs, 10 μg CobB, and the reaction 
buffer were incubated at 37 °C in a total volume of 100 μL. 
 
2.4 Results 
2.4.1 Selecting acetylation sites in MDHs  
Recently, several proteomic studies have identified lysine acetylation in E. coli MDH 
(eMDH), and lysine residues K99 and K140 were identified to be acetylated in all of these 
reports [37–39, 46, 47]. So, we chose these two positions to incorporate AcK. In human cells, 
there are two MDH isozymes, the cytosol MDH1 and mitochondrial MDH2 [71]. Human MDH2 
(hMDH2) has higher homology to eMDH than hMDH1 does [72].  
Previous proteomic studies showed that hMDH2 has four lysine residues acetylated at 
positions K185, K301, K307, and K314 [73]. So, we also chose these four positions to 
incorporate AcK as comparison. Interestingly, the alignment of eMDH and hMDH2 showed 
different patterns: the acetylation sites in eMDH are at the middle part of the primary sequence, 
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while those in hMDH2 are mainly at the C-terminus (Figure 2.S1). The acetylation site K185 in 
hMDH2 has its counterpart in eMDH at position K162 which was also selected to incorporate 
AcK as a control.  
 
Figure 2.1 AcK incorporation into MDHs. A) SDS-PAGE and western blotting analyses of 
purified MDHs and their variants. Lane 1, wild-type eMDH; lane 2, eMDH 99AcK; lane 3, 
eMDH 140AcK; lane 4, eMDH 162AcK; lane 5; wild-type hMDH2; lane 6, hMDH2 185 AcK; 
lane 7, hMDH2 301AcK; lane 8, hMDH2 307AcK; lane 9, hMDH2 314AcK. The same amounts 
of proteins were loaded. B) The enzyme activities of MDHs and their acetylated variants. The 
activities of wild-type E. coli MDH and human MDH2 were set as 1, respectively. The mean 
values and standard errors were calculated based on three replicates. 
 
2.4.2 Site-specifically incorporating lysine acetylation 
We incorporated AcK at selected positions mentioned above in both eMDH and hMDH2 
by our recently optimized AcK incorporation system which has an optimized tRNAPyl with better 
binding with E. coli elongation factor (EF-Tu), thus increasing the incorporation efficiency [65]. 
The AcK was genetically encoded by an amber stop codon (TAG) which was introduced by site-
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directed mutagenesis. Previous studies showed that the K12-derived strains have substantially 
higher acetylation than B-strain-derived BL21 cells during growth [39]. To lower the 
background of non-specific acetylation at other lysine residues, we used BL21 (DE3) strain as 
the expression host. The incorporation of AcK was confirmed by both western blotting (Figure 
2.1A) and mass spectrometry (MS) (Figure 2.S2–2.S8).  
 
2.4.3 The lysine acetylation of MDH increases its enzyme activities  
The enzyme activities of eMDH and hMDH2 as well as their acetylated variants were 
measured (Figure 2.1B). For eMDH, the acetylation at positions K99 and K140 increased the 
enzyme activity by 2.3 and 3.4 folds, individually, which is consistent with our previous study 
[65], while the acetylation at the position K162 had little effect. Our previous study also showed 
that doubly acetylated eMDH at both positions K99 and K140 had 6-fold higher enzyme activity 
than that of wild-type eMDH [65]. For hMDH2, only the acetylation at the position K307 
increased the enzyme activity by 3.9 folds, while others had no obvious effects.  
Steady-state kinetic analyses were performed with wild-type MDHs and their acetylated 
variants (Table 2.1). The lysine acetylation appeared not to affect the KM values of both 
substrates, NAD+ and malate, indicating that the increase of enzyme activities results mainly 
from the improvement of the overall turnover.  
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Table 2.1 Kinetic analyses of MDHs and acetylated variantsa 
 
 
aThe mean values and standard errors were calculated based on three replicates. The parameters 
were determined by nonlinear regression with software GraFit (Erithacus Software). 
 
2.4.4 CobB can deacetylate acetylated MDHs at specific positions  
Lysine deacetylases remove the N-acetyl amide moieties and can be broadly divided into 
two families according to their reaction mechanism: hydrolytic deacetylases and NAD+- 
dependent deacetylases which are also named as sirtuins [32, 74]. The CobB protein, a sirtuin 
family member, was found in many bacteria including E. coli and Salmonella [48, 51]. Recently, 
YcgC has been confirmed to be a hydrolytic deacetylase and target a distinct set of substrates 
from E. coli CobB, representing a novel family of prokaryotic deacetylases [75].  
To determine the deacetylation activity of the CobB protein on acetylated MDHs, K12- 
derived E. coli TOP10 strain with higher acetylation levels was used for in vivo tests [39]. The 
genes of eMDH and hMDH2 with C-terminal His6-tags were expressed and purified in wild-type 
or ΔcobB cells, individually. Western blotting was used for detecting the acetylation (Figure 
2.2A). The deletion of cobB gene increased the acetylation levels of both eMDH and hMDH2, 
indicating that CobB could deacetylate their lysine acetylation in vivo. We also measured the 
enzyme activities of MDHs from wild-type or ΔcobB cells (Figure 2.2B). The MDHs purified 
from ΔcobB cells had higher enzyme activities, which was consistent with the western blotting 
results as lysine acetylation could increase MDH activities.  
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Figure 2.2 CobB deacetylates MDH. A) Western blotting of purified MDHs from TOP10 and 
TOP10 ΔcobB cells. Lane 1 and 4 were from wild-type TOP10 cells. Lane 2 and 5 were from 
TOP10 ΔcobB cells. Lane 3 was from TOP10 ΔcobB ΔyfiQ cells. The same amounts of proteins 
were loaded. B) The enzyme activities of purified MDHs from TOP10 and TOP10 ΔcobB cells. 
The activity of eMDH purified from wild-type TOP10 cells was set as 1. The mean values and 
standard errors were calculated based on three replicates. C) Western blotting of acetylated MDH 
variants treated with the CobB protein. The acetylation levels of MDH variants after 2-hour 
incubation were compared with those without CobB treatment. The same amounts of proteins 
were loaded. 
We also performed in vitro deacetylation experiments. The optimized AcK incorporation 
system mentioned above was used to generate site-specially acetylated eMDH at positions K99, 
K140, and K162, individually, and acetylated hMDH2s at positions K185, K301, K307, and 
K314, respectively. All these MDH variants were treated with CobB protein separately. Western 
blotting was used for detecting the acetylation (Figure 2.2C). Our results showed that CobB was 
specific for positions K140 and K162 of eMDH and the position K307 of hMDH2. After 2-hour 
treatment of CobB, no detectable acetylation was observed for these three positions by western 
blotting, while the acetylation at other positions were not changed obviously. The insensitivity of 
acetyl-K99 in eMDH against CobB supports the conclusion from previous studies that although 
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CobB is the predominate deacetylase in E. coli, it could not deacetylate the majority of 
acetylation at lysine residues [39, 46, 76]. For hMDH2 acetylated variants, we also tested them 
with the counterpart of CobB in human, SIRT3, which is the major protein deacetylase in 
mitochondria [77]. Similarly, SIRT3 is only specific for acetyl-K307 of hMDH2 (Figure 2.S9).  
 
2.4.5 The acetylation of MDHs 
The acetylation of lysine residues is catalyzed by acetyltransferases which can be 
categorized into five families: the Gcn5-related N-acetyltransferase (GNAT) family, the MYST 
family, the CBP/p300 co-activators, the SRC family of co-activators, and the TAFII group of 
transcription factors [78–81]. YfiQ, a member of GNAT family, is the only known 
acetyltransferase in E. coli, required for glucose-dependent acetylation of several lysine residues 
within RNA polymerase [58] and for the acetylation of Lys544 in RNase R [61].  
To determine the acetylation activity of the YfiQ protein on eMDH, TOP10 strain (a 
K12- derivated strain with a higher acetylation level) was used for in vivo tests. The gene of 
eMDH with a C-terminal His6-tag was expressed in TOP10 ΔcobB ΔyfiQ cells and purified. 
Western blotting was used for detecting the acetylation. Compared with the eMDH which was 
expressed from TOP10 ΔcobB cells (Figure 2.2A), the deletion of yfiQ gene did not decrease the 
acetylation level of eMDH with the ΔcobB background, indicating that the YfiQ protein is not 
the major acetyltransferase for eMDH in vivo. We also measured the enzyme activity of eMDH 
from TOP10 ΔcobB ΔyfiQ cells (Figure 2.3A). eMDH purified from ΔcobB ΔyfiQ cells had a 
similar enzyme activity with eMDH purified from ΔcobB cells, indicating they had similar levels 
of acetylation which was consistent with the western blotting results.  
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Figure 2.3 Acetylation of E. coli MDH. A) The enzyme activities of purified eMDHs from 
TOP10, TOP10 ΔcobB, and TOP10 ΔcobB ΔyfiQ cells. The activity of eMDH purified from 
TOP10 cells was set as 1. The mean values and standard errors were calculated based on three 
replicates. B) Western blotting of purified eMDH from BL21(DE3) treated with the YfiQ protein 
and acetyl CoA for 2 hours. The same amounts of proteins were loaded. C) B) Western blotting 
of purified eMDH from BL21(DE3) treated with acetyl CoA or acetyl-phosphate (AcP) for 2 
hours and 12 hours, respectively. The same amounts of proteins were loaded. 
We also performed in vitro acetylation experiments. The wild type eMDH expressed and 
purified from BL21 (DE3) cells which had no detectable acetylation with western blotting 
(Figure 2.1B) was treated with purified YfiQ protein and the acetylation donor, acetyl CoA. 
Incubated with YfiQ and acetyl CoA for 2 hours, the acetylation level of eMDH had no obvious 
difference with that incubated with acetyl CoA only, indicating that YfiQ cannot acetylate 
eMDH efficiently in vitro (Figure 2.3B).  
Besides YfiQ, there are 24 members of GNAT family acetyltransferases in E. coli, 12 
with known substrates: ArgA, AstA, CitC, MnaT, PanM, PhnO, RimI, RimJ, RimL, SpeG, 
TmcA, and WecD; the other 12 proteins with unknown functions: ElaA, YafP, YedL, YhbS, 
YhhY, YiaC, YiiD, YjaB, YjdJ, YjgM, YjhQ, and YpeA [33]. We tested their functions in 
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acetylating eMDH in vitro. Similarly, incubated with individual candidate acetyltransferase and 
acetyl CoA for 2 hours, the acetylation level of eMDH had no obvious difference with that 
incubated with acetyl CoA only (Figure 2.S10). Previous studies showed chemical acetylation of 
proteins both in vitro and in vivo [39, 46, 82–85]. We also noticed that eMDH was acetylated 
after incubation with only acetyl CoA for 2 hours (Figure 2.3B). So, we determined the chemical 
acetylation of eMDH by acetyl CoA or acetyl-phosphate, respectively. eMDH expressed and 
purified from BL21(DE3) cells which has no detectable acetylation was used. Western blotting 
was used to detect the acetylation (Figure 2.3C). The results showed that both acetyl CoA and 
acetyl-phosphate could chemically acetylate eMDH at a dose-dependent manner. And the 
acetylation level of eMDH increased with the incubation time, which is consistent with the 
previous study on protein acetylation dynamics [47]. Such acetylation accumulation may also 
result from a carbon-to-nitrogen or a carbon-to-magnesium imbalance in vivo [39, 86].  
 
2.4.6 Acetylation of eMDH with different carbon sources  
Previous studies showed that the acetylation level of metabolic enzymes is higher when 
cells grow with glucose [73]. So, we determined the acetylation level of eMDH purified from 
TOP10 cells grown with different carbon sources. Clearly, glucose could increase the acetylation 
level of eMDH with a dose-dependent manner (Figure 2.4A). We also measured the enzyme 
activities of eMDH from cells with different carbon sources, and it was consistent with the 
western blotting results (Figure 2.4B). These results are consistence with previous proteomic 
studies [47], indicating the possible role of enzyme acetylation in mediating cellular adaptation 
to different environments. 
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Figure 2.4 Acetylation of E. coli MDH with different carbon sources. A) Western blotting of 
purified eMDHs from TOP10 cells grown with different carbon sources. LB medium, minimal 
medium with different glucose (Glu) concentrations (5%, 2%, 1%, or 0.5%) were used. The 
same amounts of proteins were loaded. B) The enzyme activities of purified eMDHs from 
TOP10 cells grown with different carbon sources. The activity of eMDH purified from TOP10 
cells grown with LB medium was set as 1. The mean values and standard errors were calculated 
based on three replicates. 
 
2.5 Discussion  
Classic approaches use amino acid substitutions to map functional lysine acetylation 
sites. The substitution with arginine retains a positive charge which is often utilized as a 
nonacetylated mimic, while the substitution with glutamine abolishes the positive charge which 
can act as a surrogate of acetylation [87–89]. However, such strategies sometimes do not reveal 
the real effects of lysine acetylation [90]. Here, we synthesized homogenously acetylated 
proteins at specific sites by the genetic code expansion strategy to determine the effects of 
acetylation directly, overcoming the potential problems with the substitution approach. 
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 Our kinetic analysis of MDH variants indicated that the catalytic efficiency of acetylated 
MDHs increased 2.3 to 3.4 folds (Table 2.1). The KM values of both substrates, NAD
+ and 
malate, did not change obviously, indicating that acetylation at these positions do not affect the 
substrate binding. The results also showed that the human enzyme has higher catalytic efficiency 
and much better binding of malate than those of the E. coli enzyme.  
Based on the crystal structures on eMDH (PDB ID: 1EMD) and hMDH2 (PDB ID: 
2DFD) [91], we mapped the selected acetylated residues used in this study (Figure 2.5). None of 
these acetylated sites are at substrate binding sites. It is consistent with our kinetic analyses 
which indicated that the lysine acetylation does not affect the substrates binding (Table 1). Our 
results also showed that CobB deacetylase was specific for positions K140 and K162 of eMDH 
and the position K307 of hMDH2 (Figure 2.2C). From the structures of MDHs (Figure 2.5), we 
found that these three residues are located at coiled structures. Lysine residues at position K99 in 
eMDH, positions K301 and K314 in hMDH2 are within either helical structures or sheet 
structures. These results suggested CobB favors unstructured protein domains which is consistent 
with previous studies [39, 46, 76, 92]. Interestingly, as a counterpart of eMDH position K162, 
the lysine acetylation at position K185 (at a coiled structure) in hMDH2 is resistant to the 
deacetylase (Figure 2.2C), indicating that the specificity of the deacetylase may also depend on 
primary sequence contexts, which has been proposed in the previous study [76]. And this 
difference may be an ideal target for antibacterial agent development.  
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Figure 2.5 Mapping of acetylation sites on the crystal structures of MDHs. The crystal 
structures of eMDH (PDB ID: 1EMD) and hMDH2 (PDB ID: 2DFD) were demonstrated with 
the selected acetylation sites in this study labelled. 
Based on the bioinformatical analyses, there are 25 putative GNAT family 
acetyltransferases in E. coli [78]. Some members perform Nα-acetylation such as RimL [93], 
while some members are specific for free amino acids like ArgA [94]. There are reports to 
describe the functions of only 13 GNAT members, leaving the other 12 members completely 
unknown [95]. Although some works have been done to identify the protein motifs which are 
recognized by protein acetyltransferases [95, 96], the difference between GNAT members may 
be important for their specificities for different protein substrates, thus it is necessary to 
characterize those 25 GNAT members for protein acetylation studies as we did in this study 
(Figure 2.S10). 
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3.1 Abstract 
The Escherichia coli isocitrate dehydrogenase (ICDH) is one of the tricarboxylic acid 
cycle enzymes, playing key roles in energy production and carbon flux regulation. E. coli ICDH 
was the first bacterial enzyme shown to be regulated by reversible phosphorylation. However, 
the effect of lysine acetylation on E. coli ICDH, which has no sequence similarity with its 
counterparts in eukaryotes, is still unclear. Based on previous studies of E. coli acetylome and 
ICDH crystal structures, eight lysine residues were selected for mutational and kinetic analyses. 
They were replaced with acetyllysine by the genetic code expansion strategy or substituted with 
glutamine as a classic approach. Although acetylation decreased the overall ICDH activity, its 
effects were different site by site. Deacetylation tests demonstrated that the CobB deacetylase 
could deacetylate ICDH both in vivo and in vitro, but CobB was only specific for lysine residues 
at the protein surface. On the other hand, ICDH could be acetylated by acetyl-phosphate 
chemically in vitro. And in vivo acetylation tests indicated that the acetylation level of ICDH was 
 
61 
correlated with the amounts of intracellular acetyl-phosphate. This study nicely complements 
previous proteomic studies to provide direct biochemical evidence for ICDH acetylation. 
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3.2 Introduction 
The family of isocitrate dehydrogenases (ICDHs) catalyzes the reaction of converting 
isocitrate to α-ketoglutarate and carbon dioxide in two steps: the oxidation of isocitrate to the 
intermediate oxalosuccinate and the decarboxylation of its β-carboxyl group to αketoglutarate 
[1]. Depending on the electron acceptor, ICDHs have two distinct classes: NAD+-dependent 
ICDHs (EC 1.1.1.41) and NADP+-dependent ICDHs (EC 1.1.1.42) [2, 3]. In human cells, NAD+-
dependent ICDH3 is located at the mitochondrial matrix and plays the role in energy production 
through the tricarboxylic acid (TCA) cycle, while NADP+- dependent ICDH1 and ICDH2 are 
found in the cytosol and the mitochondria respectively, shuttling electrons between the cytosol 
and the mitochondria [4]. Due to the important role in generating NADPH for cellular defense 
against oxidative damage, NADP+-dependent ICDHs have been identified to be associated with a 
number of serious human diseases such as cancer and leukemia [5, 6]. Different from eukaryotic 
cells, Escherichia coli only has the NADP+-dependent form of ICDH [7, 8], which plays both 
roles in generating energy through the TCA cycle and producing NADPH to protect cells from 
oxidative damage.  
E. coli ICDH has been known to be regulated by phosphorylation for more than 30 years 
[9, 10]. The phosphorylated serine residue at position 113 completely inactivates the enzyme, 
while dephosphorylation restores the impaired activity [11]. Such reversible phosphorylation is 
catalyzed by a single enzyme, the bifunctional ICDH kinase/phosphatase, which is essential for 
E. coli growth on acetate as sole carbon source [12]. Since isocitrate is the common substrate of 
ICDH in the TCA cycle for energy production and the isocitrate lyase (ICL) in the glyoxylate 
shunt for biosynthetic intermediate generation, regulation of ICDH is critical in controlling the 
ratio of carbon destined for cell growth and energy production [13– 15] 
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As another widely distributed post-translational modification in nature, reversible 
acetylation of lysine residues is essential for a wide range of biological processes such as gene 
expression, energy metabolism, and cell signaling. Although first identified and well-studied in 
eukaryotic cells, more and more evidence has indicated that lysine acetylation is also involved in 
a number of prokaryotic cellular functions [16–30]. Interestingly, proteomic studies have 
demonstrated that metabolic enzymes including ICDHs are favorable targets for lysine 
acetylation in both eukaryotes and prokaryotes [31]. Previous studies of eukaryotic NADP+-
dependent mitochondrial ICDH2 showed that it is regulated by lysine acetylation for defending 
reactive oxygen species under calorie restriction [32, 33]. However, E. coli ICDH has no 
sequence identity with eukaryotic ICDH2, so the effect of lysine acetylation on E. coli ICDH still 
remains unclear. Recently, we have characterized lysine acetylation of another TCA cycle 
enzyme, malate dehydrogenase (MDH) in E. coli [34]. Our results showed that lysine acetylation 
could increase the MDH activity and was regulated by the CobB deacetylase and intracellular 
acetyl-phosphate, as well as the carbon source in growth media. In this study, our results 
demonstrated that lysine acetylation of ICDH has distinct effects but also shares common 
features with the acetylation of MDH. To our best knowledge, this is the first biochemical 
characterization of lysine acetylation of bacterial type NADP+-dependent ICDH. 
 
3.3 Materials and Methods 
3.3.1 General molecular biology  
Chemical compounds in this study were purchased from Sigma-Aldrich, VWR 
International, or Chem-Impex International. DH5α cells were used for general cloning. 
Polymerase chain reaction (PCR) reactions and plasmid constructions were performed by using 
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the NEBuilder HiFi DNA Assembly Kit (New England Biolabs). Point mutations of the icd gene 
in the plasmid were made by the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). 
Inactivation of genes from the E. coli genome was performed by the recombination approach 
[82]. The strains and plasmids used in this study is listed in Table 3.3.S1. CobB, YcgC, RutR, 
RcsB, and YfiQ proteins were expressed from the ASKA collection and purified by previous 
protocols [83].  
Protein concentrations were measured by the Bradford Protein Assay (Bio-Rad). The 
purified ICDH and its variants were fractionated on a 4–20% SDS-PAGE gel and visualized by 
the Bio-Safe Coomassie Stain (Bio-Rad). For western blotting, the fractionated SDSPAGE gel 
was transferred onto a PVDF membrane by using the Trans-Blot Turbo Transfer System (Bio-
Rad). The PVDF membrane was incubated at room temperature with gentle shacking in the 
blocking buffer (5% bovine serum albumin, 0.1% Tween 20 in Tris-buffered saline) for 2 h. The 
horseradish peroxidase (HRP)-conjugated acetyllysine (AcK) antibody (Cell Signaling 
Technology) was diluted 1:1000 with the blocking buffer and soaked the blocked PVDF 
membrane overnight at 4 °C. The membrane was prepared for chemiluminescence detection by 
using Pierce ECL Western Blotting substrates (Thermo Scientific). 
 
3.3.2 Expression and purification of acetylated ICDH variants  
The protocols followed previous studies with slightly modifications [54]. The genes of 
the ICDH and its variants were cloned into the pCDF-1b plasmid (EMD Millipore) with a C-
terminal His6-tag, and transformed into BL21 (DE3) cells (New England Biolabs) together with 
the pTech plasmids harboring the AcK incorporation system for expression [56, 84]. The 
expression strain was grown on 500 mL of LB medium supplemented with 100 μg/mL 
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streptomycin and 50 μg/mL chloramphenicol at 37°C to an absorbance of 0.6–0.8 at 600 nm. 
Then protein expression was induced by the addition of 0.1 mM Isopropyl β-D-1- 
thiogalactopyranoside (IPTG). For AcK-containing protein expression, media were additionally 
supplemented with 10 mM AcK and 20 mM nicotinamine (NAM). Cells were incubated at 25°C 
for an additional 12 h and harvested by centrifugation at 3200 × g for 15 min at 4 °C. The cell 
paste was suspended in 12 mL of lysis buffer [50 mM Tris (pH 7.8), 300 mM NaCl, 20 mM 
imidazole, 20 mM NAM, and 5 mM β-mercaptoethanol with cocktail protease inhibitors 
(Roche), and broken by sonication. The crude extract was centrifuged at 18,000 × g for 20 min at 
4°C. The soluble fraction was filtered through a 0.45-μm membrane and loaded onto a column 
containing 2 mL of Ni-NTA resin (Qiagen) previously equilibrated with 20 mL lysis buffer. The 
column was then washed with 20 mL of washing buffer [50 mM Tris (pH 7.8), 300 mM NaCl, 
and 40 mM imidazole]. The protein bound to the column was finally eluted with 2 mL of elution 
buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 150 mM imidazole]. The purified protein was 
dialyzed with 2 L of storage buffer [25 mM Tris (pH 7.8), 10 mM NaCl, 1 mM dithiothreitol 
(DTT), and 50% glycerol], and stored at −80°C.  
 
3.3.3 The ICDH enzyme assay and kinetic analyses  
The enzyme activity assay followed the previous protocol [85]. The reaction was 
performed in the buffer containing 25 mM MOPS, 100 mM NaCl, 5 mM MgCl2, and 1 mM DTT 
at 25°C. The reaction was carried out by mixing 30 ng ICDH or its variants, 1 mM isocitrate, and 
1 mM NADP+ in a total volume of 100 μL. The rates of reaction were determined by monitoring 
the production of NADPH at 340 nm. For kinetic analyses, the concentration of one substrate 
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was varied while the other substrate was at a fixed concentration of 5 mM. The kinetic 
parameters were calculated from nonlinear regression by software Grafit (Erithacus Software). 
 
3.3.4 Mass spectrometry (MS) analyses  
The full-length MS analyses were performed by the University of Arkansas Statewide 
Mass Spectrometry Facility, following the previous protocol [79]. Purified proteins were 
dialyzed with pure water, diluted to 0.05 mg/mL, and analyzed by a Bruker UltraflexII TOF-
TOF with a MALDI ionization source. Spectra were obtained in the positive ion, linear mode. 
The LC-MS/MS analyses were performed by Yale University Keck Proteomics Facility, 
following previous protocols [86, 87]. Proteins were digested in gel by trypsin and analyzed by 
LC-MS/MS on an LTQ Orbitrap XL equipped with a nanoACQUITY UPLC system. The 
Mascot search algorithm was used to search for the appropriate noncanonical substitution. 
 
3.3.5 The in vitro acetylation assays  
The acetylation assay was modified from previous experiments [83]. The reaction was 
performed in the buffer containing 50 mM Tris (pH 7.8), 0.1 mM EDTA, 10% glycerol, 1 mM 
DTT and 10 mM sodium butyrate. The acetylation was carried out by mixing 10 μg ICDH, 10 μg 
of YfiQ, 0.2 mM acetyl CoA in a total volume of 100 μL and incubated at 37°C for 2 hours. For 
non-enzymatic acetylation, 10 μg ICDH was incubated with varying concentrations of acetyl-
phosphate at 37°C for different time spans. 
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3.3.6 The in vitro deacetylation assays  
The deacetylation reaction was slightly modified from the previous study [88]. The 
reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM MgCl2, 1.0 mM 
NAD+, 1 mM DTT and 10 % glycerol. The deacetylation was carried out by mixing 10 μg 
acetylated ICDH variants, 10 μg CobB or YcgC proteins in a total volume of 100 μL and 
incubated at 37°C for 2 hours. 
 
3.4 Results 
3.4.1 Site-specifically incorporating lysine acetylation into ICDH  
Proteomic studies of E. coli have identified totally more than 20 lysine residues to be 
acetylated in ICDH [35–44]. However, the sets of acetylation sites from these studies are distinct 
from each other, mostly because of the differences in E. coli strains, growth conditions, 
acetylated peptide detection methods, and mass spectrometry resolutions. Thus, we chose lysine 
residues for later studies based on both proteomic [35–44] and structural studies [45–52] by three 
criteria: 1) those that have been identified in more than four independent proteomic studies; 2) 
those that are located at the active site or subunit interfaces; 3) those that are conserved among 
different organisms. Based on these standards, eight lysine residues (K55, K100, K142, K177, 
K230, K235, K242, and K350) were selected. Among them, only K100 has not been identified to 
be acetylated before, but it was reported to be succinylated instead [44, 53]. We chose it as a 
control because of its essential role in catalysis and substrate binding [52]. 
Then we applied the genetic code expansion approach to incorporate AcK directly into 
those selected positions by our recently optimized protocol individually [54]. This approach 
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utilizes an engineered Methanosarcina barkeri pyrrolysyl-tRNA synthetase [55] and an 
optimized cognate tRNApyl [56] to read through the TAG stop codon in the gene of ICDH 
introduced by site-directed mutagenesis as AcK, thus producing homogeneously acetylated 
ICDH variants at selected sites [57, 58]. To reduce the background of non-specific acetylation at 
other lysine residues, we used the BL21 (DE3) strain as the expression host which was shown to 
have significantly lower levels of protein acetylation than E. coli K12-derived strains [37]. 
Indeed, the wild-type ICDH purified from BL21 (DE3) cells had no detectable acetylation by 
western blotting, while site-specifically acetylated ICDH variants all had clear bands against the 
AcK antibody (Figure 3.1a). Mass spectrometry (MS) analyses confirmed that the incorporation 
of AcK was at selected positions respectively (Figure 3.S1–3.S9). 
 
Figure 3.1 The effect of acetylation at single lysine residues. a) SDS-PAGE and western 
blotting analyses of purified ICDH and its variants. Lane 1, wild-type ICDH; lane 2, ICDH-
55AcK; lane 3, ICDH-100AcK; lane 4, ICDH-142AcK; lane 5; ICDH-177AcK; lane 6, ICDH-
230AcK; lane 7, ICDH-235AcK; lane 8, ICDH-242AcK; lane 9, ICDH-350AcK. The same 
amounts of proteins were loaded. b) Relative enzyme activities of ICDH and its variants with 
acetyllysine (AcK) or glutamine (Gln) substitution. The activity of wild-type E. coli ICDH was 
set as 1. Mean values and standard deviations were calculated based on three biological 
replicates 
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3.4.2 Determining the effect of lysine acetylation on the ICDH activity  
The enzyme activities of ICDH and its acetylated variants were measured (Figure 3.1b). 
The effect of acetylation on the enzyme activity was different site by site. Acetylation at K55 or 
K350 significantly increased the activity, while acetylation at K142, K177, or K242 only had 
small enhancement. On the other hand, acetylation at K235 lost about 40% of the activity, while 
acetylation at K100 or K230 almost completely eliminated the enzyme activity. 
As a classic approach, glutamine is commonly used as a mimic of acetylated lysine. 
Thus, we also substituted selected lysine residues with glutamine respectively, and measured the 
activities of those K-to-Q variants as a comparison with the direct AcK incorporation approach. 
Interestingly, the results from glutamine substitution were quite different from those by direct 
acetyllysine incorporation (Figure 3.1b). Substituting lysine with glutamine decreased enzyme 
activities at all tested positions. Glutamine substitution at K100 or K230 abolished the enzyme 
completely which was similar to the AcK incorporation approach but results for other positions 
were quite different from two approaches. For example, replacement of K55 by glutamine 
decreased the enzyme activity dramatically, but direct incorporation of acetyllysine at K55 
significantly increased the activity (Figure 3.1b).  
To illustrate how acetylation affects the enzyme activity, steady-state kinetic analyses 
were performed for the wild-type ICDH and its acetylated variants (Table 3.1). Acetylation at 
K55 or K350 increased the turnover number, while acetylation at K142, K177, or K242 had no 
significant effects on kinetic parameters. On the other hand, acetylation at K100 decreased the 
catalytic efficiency by 106 -fold, consistent with the previous study in which K100 was replaced 
with Met, Gln, or His [52]. Acetylation at K230 dramatically decreased both the turnover 
number and the affinity of isocitrate which aligned with previous mutagenesis studies on ICDH 
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[49, 59], while acetylation of K235 halved the turnover number without affecting binding of both 
substrates. 
Table 3.1 Kinetic analyses of ICDH and its acetylated variants 
 
The mean values and standard deviations were calculated based on three biological replicates. 
For KM determination, one substrate was varied with six different concentrations, while the other 
substrate was fixed at a concentration of 5 mM. The parameters were determined by nonlinear 
regression with software GraFit (Erithacus Software). 
Proteomic studies indicated that E. coli ICDH could be multiply acetylated 
simultaneously [35–44], so possible cooperative effects of multiple lysine acetylation on ICDH 
were tested. Starting with simpler cases, we applied the genetic code expansion strategy to 
incorporate AcK at two sites of selected lysine residues simultaneously. As a representative, 
K55, of which acetylation increased the enzyme activity significantly, was chosen to be 
acetylated in all variants. Totally seven dual-acetylated ICDH variants were generated (ICDH-
55AcK/100AcK, ICDH-55AcK/142AcK, ICDH-55AcK/177AcK, ICDH-55AcK/230AcK, 
ICDH-55AcK/235AcK, ICDH-55AcK/242AcK, and ICDH-55AcK/ 350AcK). Both western 
blotting and mass spectrometry analyses confirmed the simultaneous incorporation of AcK at 
selected positions (Figure 3.2a, Figure 3.S10– 3.S17). Then we measured the enzyme activities 
of these dual-acetylated variants (Figure 3.2b). However, the improving effect of acetylation at 
K55 could not recover impaired activities caused by acetylation at K100 and K230, implying 
their essential roles in catalysis or substrate binding. 
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Figure 3.2 The effect of simultaneous acetylation at two lysine residues. a) SDS-PAGE and 
western blotting analyses of purified ICDH and its variants. Lane 1, wild-type ICDH; lane 2, 
ICDH-55AcK/100AcK; lane 3, ICDH-55AcK/142AcK; lane 4, ICDH-55AcK/177AcK; lane 5; 
ICDH-55AcK/230AcK; lane 6, ICDH-55AcK/235AcK; lane 7, ICDH-55AcK/242AcK; lane 8, 
ICDH-55AcK/350AcK. The same amounts of proteins were loaded. b) Relative enzyme 
activities of ICDH and its variants with acetyllysine (AcK) at two lysine sites simultaneously. 
The activity of wild-type E. coli ICDH was set as 1. Mean values and standard deviations were 
calculated based on three biological replicates. 
Due to the existence of endogenous deacetylases in cells, lysine residues usually are not 
acetylated completely. Thus, besides above in vitro experiments in which lysine residues were 
homogeneously acetylated, we also performed in vivo studies which could reflect the real 
situation in living cells. The E. coli K12-derived BW25113 strain was used for all in vivo 
experiments in this study (unless indicated). Firstly, we compared the acetylation levels of ICDH 
purified from BW25113 cells grown in LB media or M9 media with 0.2% glucose. Cells were 
grown at 37°C for 8 hours after inoculation. The native ICDH was purified by the established 
protocol with 50 mM nicotinamine (the deacetylase inhibitor) in all purification buffers [60]. The 
acetylation of purified ICDHs was determined by western blotting (Figure 3.3a). ICDH purified 
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from LB media had no detectable acetylation, while that from glucose media had a clear band, 
indicating glucose could induce the acetylation of ICDH in vivo, which is consistent with 
previous proteomic studies [37, 41, 43]. Then we measured their enzyme activities (Figure 3.3b). 
ICDH purified from glucose media with a higher acetylation level lost about 60% of the activity 
compared to that from LB media. We were not surprised at these results, because our in vitro 
experiments above showed that the acetylation at key residues such as K100 and K230 almost 
impaired the enzyme activity completely which could not be recovered by acetylation at other 
positions even those like K55 of which acetylation could increase the enzyme activity (Figure 
3.2b). 
 
Figure 3.3 The effect of acetylation on ICDH in vivo. a) SDS-PAGE and western blotting of 
purified ICDHs from LB media (lane 1) and M9 media with 0.2% glucose (lane 2). The same 
amounts of proteins were loaded. b) The enzyme activities of purified ICDHs from LB media 
and M9 media with 0.2% glucose. The activity of ICDH purified from LB media was set as 1. 
The mean values and standard deviations were calculated based on three biological replicates. 
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3.4.3 Deacetylation of ICDH  
The acetyl on the ε-amino group of lysine residues is Table 3.1, and its removal needs a 
category of enzymes called lysine deacetylases [61, 62]. Till now, there are only two known 
lysine deacetylases identified in E. coli: the CobB protein, a NAD+-dependent sirtuin class 
deacetylase [63–65], and the YcgC protein, a NAD+-independent serine hydrolase family 
member with a distinct set of substrates from CobB [66].  
 
Figure 3.4 Deacetylation of ICDH. a) SDS-PAGE and western blotting of purified ICDHs from 
wild-type BW25113 (lane 1), BW25113 ΔycgC (lane 2), and BW25113 ΔcobB (lane 3). b) 
Western blotting of site-specifically acetylated ICDH variants treated with CobB for 2 hours. c) 
Western blotting of site-specifically acetylated ICDH variants treated with YcgC for 2 hours. 
The same amounts of proteins were loaded in all the experiments. d) Relative enzyme activities 
of ICDH and its acetylated variants after treatment with CobB or YcgC. The activity of wild-
type E. coli ICDH without deacetylase treatment was set as 1. Mean values and standard 
deviations were calculated based on three biological replicates. 
To determine the deacetylation of ICDH by CobB and YcgC, the acetylation levels of 
native ICDHs purified from wild-type, ΔycgC, and ΔcobB of BW25113 cells grown in M9 media 
with 0.2% glucose were compared by western blotting (Figure 3.4a). The deletion of cobB 
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increased the acetylation level of ICDH, consistent with previous quantitative proteomic studies 
[39–42], while inactivation of ycgC had no obvious effect. 
A previous study showed that inactivation of the cobB gene increased the acetyl-
phosphate concentration in cells [39], and acetyl-phosphate could increase protein acetylation 
globally [37, 41]. Thus, although the deletion of the cobB gene increased the acetylation level of 
ICDH (Figure 3.4a), we cannot conclude that CobB can deacetylate ICDH directly. To provide 
direct evidence, we performed in vitro deacetylation experiments. The site-specifically acetylated 
ICDH variants generated by the genetic code expansion strategy were treated with the purified 
CobB protein, respectively. Western blotting was used for detecting the acetylation (Figure 
3.4b). The results showed that CobB was only specific for position 55, 142, 177, or 350. After 2-
hour treatment of CobB, no detectable acetylation was observed for these positions by western 
blotting, while acetylation at other positions were not changed obviously, which could explain 
the detectable acetylation with an intact cobB gene in wildtype BW25113 cells (Figure 3.3a). 
Those selected lysine residues were mapped onto the crystal structure of ICDH [46] (Figure 
3.S18). CobB-sensitive sites (K44, K142, K177, and K350) are all located at ICDH surfaces, 
while CobB-resistant sites (K100, K230, K235, and K242) are internal and close to the active 
site. Although the CobB substrate specificity is varied by different criterions, a common feature 
is to be located at protein surfaces [37, 42]. The same in vitro deacetylation experiments were 
performed for the YcgC protein (Figure 3.4c). Consistent with in vivo experiments, no significant 
changes were observed after 2-hour treatment of YcgC at all sites tested. RutR, the known 
substrate of YcgC [66], was used as a positive control to show that YcgC was active in this study 
(Figure 3.S19). We also performed enzyme assays to measure the activities of those site-
specifically acetylated ICDH variants after CobB and YcgC treatment (Figure 3.4d). Treatment 
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of the variant acetylated at position 55, 142, 177, or 350 with the CobB protein decreased its 
activity to the level of wild-type enzyme, consistent with above western blotting results which 
showed that CobB was specific for those sites. 
 
3.4.4 The acetylation of ICDH  
Currently, it is believed that lysine acetylation in E. coli has two major mechanisms: the 
acetyl CoA-dependent enzymatic process and the acetyl-phosphate-dependent chemical reaction 
[16–22]. YfiQ is the only known protein acetyltransferase in E. coli which belongs to the Gcn5-
related N-acetyltransferase family [67, 68]. To determine the acetylation of ICDH by YfiQ, the 
acetylation levels of native ICDHs purified from wild-type, ΔyfiQ, ΔcobB, and ΔyfiQ ΔcobB of 
BW25113 cells grown in M9 media with 0.2% glucose were compared by western blotting 
(Figure 3.5a). The deletion of yfiQ did not decrease the acetylation level of ICDH expressed in 
cells with or without the ΔcobB background, indicating that ICDH is not the substrate of YfiQ in 
vivo, which is consistent with data from proteomic studies [37, 40–42]. To provide direct 
evidence, we also performed in vitro acetylation experiments. The wild-type ICDH expressed 
and purified from BL21 (DE3) cells was treated with purified YifQ and 0.2 mM acetyl CoA. 
After 2-hour incubation, ICDH had no detectable acetylation, indicating that ICDH is not the 
substrate of YfiQ in vitro either (Figure 3.S20). 
Then, we tested the chemical acetylation by acetyl-phosphate alone in vitro. The wild-
type ICDH expressed and purified from BL21 (DE3) cells was treated with acetyl-phosphate at 
concentrations of 200 μM, 3 mM, and 12 mM, corresponding to estimated intracellular acetyl-
phosphate concentrations at the exponential phase, the stationary phase, and the ΔackA 
background which accumulates acetyl-phosphate, respectively [37, 69, 70]. Western blotting was 
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used to determine acetylation levels (Figure 3.5b). Clearly, acetyl-phosphate could chemically 
acetylate ICDH in both dose- and time-dependent manners in vitro which aligned with proteomic 
studies [37, 41, 43]. The acetyl-phosphate-treated ICDH was then analyzed by LC-MS/MS to 
determine acetylated lysine sites. Besides the eight selected sites in above in vitro studies, we 
identified additionally acetylated lysine residues at positions 4, 20, 47, 73, 166, 174, 265, 273, 
278, 378, and 387 (Figure 3.S21–S31). Most of them are located at the protein surface which is 
consistent with the specificity of acetyl-phosphatedependent acetylation [41, 43]. But we did not 
detect acetylation at positions 12, 58, 186, 199, 267, and 401 which have been reported by 
proteomic studies before [31]. Although this could result from differences in strains, growth 
conditions, and mass spectrometry resolutions, it also indicates that acetylation at those sites may 
need additional cofactors, coenzymes, or unknown protein acetyltransferases. 
Reversely, among those acetylated lysine residues detected in in vitro acetylation 
experiments, K47, K73, and K278 as well as K100 have never been identified to be acetylated in 
any proteomic studies before, indicating the differences between the in vitro study and the in vivo 
process. Thus, we performed in vivo tests for acetyl-phosphatedependent acetylation of ICDH. 
Acetyl-phosphate is the intermediate of the phosphotransacetylase (Pta) – acetate kinase (AckA) 
pathway [71]. Pta catalyzes the reversible conversion between acetyl CoA and acetyl-phosphate, 
while AckA catalyzes the reversible conversion between acetate and acetyl-phosphate. When 
cells are grown in media without using acetate as carbon source, inactivation of pta will block 
the acetyl-phosphate production, while ΔackA accumulates acetyl-phosphate [71]. The 
acetylation levels of native ICDHs purified from wild-type, Δpta, and ΔackA of BW25113 cells 
grown in M9 media with 0.2% glucose were compared by western blotting (Figure 3.5c). As 
expected, acetylation of ICDH was correlated with intracellular concentrations of acetyl-
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phosphate. ΔackA increased the acetylation level of ICDH which is consistent with proteomic 
studies [37, 41]. Although our in vitro studies demonstrated that acetyl-phosphate could acetylate 
ICDH without any enzymes, we could not exclude the existence of specific protein 
acetyltransferases for ICDH acetylation in vivo because of the different sets of acetylated lysine 
residues detected by in vitro and in vivo approaches. 
 
 
Figure 3.5 Acetylation of ICDH. a) SDS-PAGE and western blotting analyses of purified 
ICDHs from BW25113 wild-type (lane 1), ΔyfiQ (lane 2), ΔcobB (lane 3), and 
ΔyfiQ ΔcobB (lane 4). b) SDS-PAGE and western blotting analyses of purified ICDH treated 
with different concentrations of acetyl-phosphate (AcP). C) SDS-PAGE and western blotting 
analyses of purified ICDHs from wild-type BW25113 (lane 1), Δpta (lane 2), and ΔackA (lane 3). 
The same amounts of proteins were loaded in all the experiments. 
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3.5 Discussion 
By site-specifically incorporating acetyllysine into selected lysine positions, we provided 
direct biochemical evidence for the effect of acetylation on ICDH site by site. Besides the key 
residues K100 and K230 in catalysis and substrate binding which have already been 
characterized by mutational, kinetic, and structural studies before [46, 49, 50, 52, 59], we also 
showed that acetylation of K55 and K350 could increase the activity (Figure 3.1a) which is 
totally unknown before. Although crystal structures of the ICDH K55AcK and ICDH K350AcK 
variants are needed to demonstrate the mechanism in detail, we could still use existing ICDH 
crystal structures to propose acetylation effects (Figure 3.6). K350 is located at the entrance of 
the active site and is close to the substrate NADP+. Although K350 does not contact with NADP+ 
directly, the removal of the positive charge of the lysine side chain may facilitate NADP+ binding 
as shown in the kinetic analysis (Table 3.3.1). On the other hand, K55 is located at the back side 
of the active site, but it interacts with three hydrophobic residues (L375, I413, and M416) in two 
helices which form part of the active site. Acetylation neutralizes the positive charge of K55 side 
chain, thus facilitating its interactions with those hydrophobic side chains which may induce 
conformational changes to improve the catalysis.  
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Figure 3.6 Mapping of K55 and K350 on the ICDH structure. K55 and K350 were mapped 
on the structure of the ICDH dimer (PDB ID: 4aj3). Two subunits were colored with red and 
green separately. Only the side chains of labelled residues were shown. 
During growth of E. coli on acetate, the glyoxylate shunt pathway bypasses two steps in 
the TCA cycle, generating succinate, malate, and free coenzyme A from isocitrate to replenish 
central metabolism with biosynthetic precursors [72]. The first enzyme in the glyoxylate bypass, 
isocitrate lyase (ICL), is the direct competitor of ICDH for isocitrate. The partition of carbon flux 
between ICDH and ICL at the junction of isocitrate is well controlled to balance energy 
production and cell growth in different growth stages and conditions [14, 15, 73]. As the first 
prokaryotic enzyme known to be regulated by phosphorylation, ICDH has been well studied on 
its regulation by the bifunctional ICDH kinase/phosphatase [9, 12, 74]. ICL was also shown to be 
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phosphorylated at a histidine residue [75–77], but it is more sensitive to the concentration of 
isocitrate in cells [14, 15, 73]. Interestingly, Both ICDH and ICL are acetylated at multiple lysine 
residues which could be induced by glucose in growth media [37, 40, 41, 43]. A previous study 
showed that ICL activity decreased with acetylation [40]. And our study here indicated that 
acetylation could also impair the ICDH activity (Figure 3.3b). However, the net effect of lysine 
acetylation on dividing isocitrate into two pathways needs to be determined in future studies.  
Another open question is whether phosphorylation and acetylation have crosstalk for 
regulating ICDH and IDL for the carbon flux partition. Firstly, proteomic data showed that the 
bifunctional ICDH kinase/phosphatase is also acetylated at multiple lysine residues [31], but 
these acetylation targets have not been confirmed and further characterized. Secondly, the 
acetylation of ICDH may affect its own phosphorylation, since many acetylated lysine residues 
studied in this work are located close to S113 which is the key residue for reversible 
phosphorylation [51, 78]. And our recently developed genetic incorporation system for 
simultaneous acetylation and phosphorylation could be a useful tool to answer these questions 
[79]. 
 Because of the easy handling, glutamine has been widely used as a mimic of acetylated 
lysine to study effects of acetylation on protein structures, functions, and interactions. However, 
the difference between the structures of glutamine and acetyllysine could be easily ignored. The 
length of glutamine side chain is about 6 Å, while that of acetyllysine is approximately 10.5 Å. 
Such difference could cause unexpected results [80, 81]. Indeed, in this study, we showed that 
the classic glutamine mutagenesis method and the genetic acetyllysine incorporation approach 
provided opposite results in some cases such as acetylation at K55 of ICDH (Figure 3.1b).  
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4.1 Abstract 
The citrate synthase (CS) catalyzes the first reaction of the tricarboxylic acid cycle, 
playing an important role in central metabolism. The acetylation of lysine residues in the 
Escherichia coli Type II CS has been identified at multiple sites by proteomic studies, but their 
effects remain unknown. In this study, we applied the genetic code expansion strategy to 
generate 10 site-specifically acetylated CS variants which have been identified in nature. 
Enzyme assays and kinetic analyses showed that lysine acetylation could decrease the overall CS 
enzyme activity, largely due to the acetylation of K295 which impaired the binding of acetyl-
coenzyme A. Further genetic studies as well as in vitro acetylation and deacetylation assays were 
performed to explore the acetylation and deacetylation processes of the CS, which indicated that 
the CS could be acetylated by acetyl-phosphate chemically and be deacetylated by the CobB 
deacetylase 
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4.2 Introduction 
The citrate synthase (CS) (EC 2.3.3.1) catalyzes the reaction of condensing acetyl CoA 
with oxaloacetate (OAA) to form citrate and CoA by three steps: enolization of the thioester 
group of acetyl CoA, condensation of the enolate anion with OAA, and hydrolysis of the citryl-
thioester [1]. This step is not only the first reaction of the tricarboxylic acid (TCA) cycle for 
central metabolism but also a key step in amino acid biosynthesis, thus the CS can be found in 
almost all living organisms. Although catalyzing the same reaction, there are two types of CSs in 
nature [2]. Type I CSs are found in eukaryotes, archaea, and Gram-positive bacteria. They form 
homodimers with the active site located between two independently folded domains, which are 
partially closed by induced fit upon substrate binding [3]. On the other hand, Type II CSs are 
only found in Gram-negative bacteria, and share highly identical amino acid sequences with 
Type I CSs [4]. Although the Type II CS forms a hexamer rather than a dimer, it could be 
considered as a trimer of homodimers with similar structures of Type I CS dimers [3].  
Besides structures, the regulation of CSs by NADH has also been well studied. It was 
found that the Type II CS from Escherichia coli was specifically and strongly inhibited by 
NADH with an allosteric mechanism, and such inhibition could be alleviated by high salt or 
basic conditions [5]. Later, the crystal structure of the E. coli Type II CS demonstrated that the 
NADH binding site was close to the dimer–dimer interface [6]. Since Type I CSs are 
homodimers, they cannot form the NADH-binding site, which explains the insensitivity of Type 
I CSs to NADH. It was proposed that Type II CSs were evolved from Type I CSs by building 
new contact surfaces for dimers and the regulatory site for NADH binding [6]. It should be noted 
that the NADH-dependent allosteric mechanism is not found in all Type II CSs. For example, the 
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CS from Acetobacter aceti also forms a hexamer, but cannot be inhibited by NADH, possibly 
due to the missing of key residues for NADH binding [7].  
Recently, it has been shown that the eukaryotic Type I CS could be regulated by lysine 
acetylation. SIRT3, a deacetylase, was shown to deacetylate and increase CS activity [8]. 
Although firstly discovered and extensively studied in eukaryotic histones and transcription-
associated factors, lysine acetylation is also known to play important roles in bacterial 
physiology [9–12]. Acetylome studies have identified multiple lysine acetylation sites in the E. 
coli Type II CS [13], but their functions are still unknown. Our group has studied the lysine 
acetylation of two TCA cycle enzymes, malate dehydrogenase (MDH) and isocitrate 
dehydrogenase (ICDH) and showed that lysine acetylation had different effects on these two 
TCA enzymes [14,15]. In this study, we characterized lysine acetylation of the E. coli Type II CS 
and explored its modification processes. 
 
4.3 Materials and Methods 
4.3.1 General molecular biology  
General molecular biology chemicals and bacterial growth media were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), VWR International (Radnor, PA, USA), or Chem-Impex 
International (Wood Dale, IL, USA). Plasmid were constructed by following the protocol of the 
NEBuilder HiFi DNA Assembly Kit (New England Biolabs, Ipswich, MA, USA). Point 
mutations of the gltA gene were generated by following the protocol of the Q5 Site-Directed 
Mutagenesis Kit (New England Biolabs). Strains and plasmids used in this study are listed in 
Table 4.S1. 
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Protein concentrations were determined by the Bradford Protein Assay (Bio-Rad, 
Hercules, CA, USA). For western blotting, purified CS and its variants were fractionated on a 4–
20% SDS-PAGE gel and transferred to the PVDF membrane. The horseradish peroxidase 
(HRP)-conjugated acetyllysine (AcK) antibody (Cell Signaling Technology, Danvers, MA, 
USA) was used as the primary antibody, and chemiluminescence was detected by using Pierce 
ECL Western Blotting substrates (Thermo Scientific, Waltham, MA, USA).  
 
4.3.2 Expression and purification of acetylated CS variants  
Wild-type CS and its variants were expressed from the pCDF-1b plasmid (EMD 
Millipore, Burlington, MA, USA) with a C-terminal His6-tag in BL21 (DE3) cells (New England 
Biolabs). The protocols of purification were described in previous studies with slightly 
modifications [28]. The expression strain was grown in LB medium. The protein expression was 
induced by 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when cell grew to OD600 nm 
0.6. For AcK-containing protein expression, media were additionally supplemented with 10 mM 
AcK and 20 mM nicotinamine (NAM). Cells were incubated at 30 °C for an additional 4 h and 
harvested by centrifugation. Cells were broken by sonication in 12 mL of lysis buffer [50 mM 
Tris (pH 7.8), 300 mM NaCl, 20 mM imidazole, 20 mM NAM, and 5 mM β-mercaptoethanol 
with cocktail protease inhibitors (Roche, Basel, Switzerland). The crude extract was centrifuged 
at 18,000 x g for 20 min at 4 °C. The soluble fraction was filtered through a 0.45-µm membrane 
and loaded onto a column containing 2 mL of Ni-NTA resin (Qiagen, Hilden, Germany) 
previously equilibrated with 20 mL lysis buffer. The column was then washed with 20 mL of 
washing buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 40 mM imidazole], and then eluted 
with 2 mL of elution buffer [50 mM Tris (pH 7.8), 300 mM NaCl, and 150 mM imidazole]. For 
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storage, the purified protein was dialyzed with 2 L of 25 mM Tris (pH 7.8), 10 mM NaCl, 1 mM 
dithiothreitol, and 50% glycerol, and stored at 80 °C. 
 
4.3.3 The CS enzyme assay and kinetic analyses  
The enzyme activity assay was performed by following the previous protocol. It is based 
on the reaction of CoASH with Ellman’s reagent DTNB (5,5-dithio-bis-(2-nitrobenzoic acid)), 
which has the absorbance at 412 nm. The reaction was performed in the buffer containing 20 
mM Tris (pH7.8), 1 mM EDTA, 0.1 M KCl, 0.1 mM DTNB, 0.1 mM OAA, 0.1 mM acetyl CoA, 
and 50 ng CS or its variants at 25°C. The kinetic parameters were determined from nonlinear 
regression (Erithacus Software, East Grinstead, UK) by varying the concentration of one 
substrate while the other substrate concentration was fixed.  
 
4.3.4 Mass spectrometry analyses  
The full-length MS analyses were performed by following the previous protocol [40]. 
Purified proteins were diluted to 0.05 mg.mL-1 with purified water, and then analyzed by 
MALDI-TOF. The LC-MS/MS analyses were performed by following the previous protocol 
[41]. Proteins were digested in gel by trypsin and analyzed by LC-MS/MS on an LTQ Orbitrap 
XL equipped with a nanoACQUITY UPLC system. The Mascot search algorithm was used to 
search for the substitution of the lysine residue with AcK.  
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4.3.5 The in vitro acetylation assays  
The acetylation assay was performed by following the protocol described in the previous 
study [42]. The reaction was performed in the acetylation buffer [50 mM HEPES (pH 7.0), 0.1 
mM EDTA, 10% glycerol, 1 mM DTT, and 10 mM sodium butyrate]. The acetylation reaction 
was initiated by mixing 10 µg CS, 10 µg of YfiQ, 0.2 mM acetyl CoA, or varied concentrations 
of AcP in a total volume of 100 µL, and then incubated at 37 °C for 1 h.  
 
4.3.6 The in vitro deacetylation assays 
The deacetylation assay was performed by following the protocol described in the 
previous study [43]. The reaction was performed in the deacetylation buffer [50 mM HEPES (pH 
7.0), 5 mM MgCl2, 1.0 mM NAD
+, 1mM DTT, and 10% glycerol]. The deacetylation reaction 
was initiated by mixing 10 µg acetylated CS variants, 10 µg CobB proteins in a total volume of 
100 µL and incubated at 37 °C for 1 h. 
 
4.4 Results 
4.4.1 Generating site-specifically acetylated CS variants  
To explore the impact of acetylation on the E. coli CS, we first studied the site-specific 
effects of those acetylation events, which could provide direct biochemical evidence for CS 
acetylation. To avoid biased selection, we chose all the lysine residues that have been identified 
to be acetylated in nature by at least two independent acetylome studies, which were K38, K168, 
K283, K295, K310, K328, K356, K405, K418, and K422. 
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Site-directed mutagenesis of lysine to glutamine has been used commonly to study 
protein acetylation. However, our previous study showed that such method sometimes could 
draw opposite conclusions with those derived from the approach of direct incorporation of 
acetyllysine (AcK) [15]. So, in this study, we utilized an optimized system to produce purely 
acetylated CS variants at specific sites listed above by the genetic code expansion strategy 
individually [27]. To lower the background of nonspecific acetylation for in vitro assays, we 
used the BL21(DE3) strain as the host, which has much lower acetylation levels than E. coli K12 
strains [18]. Indeed, the wild-type CS overexpressed in BL21(DE3) cells had no detectable 
acetylation (Figure 4.1), consistent with our previous studies on MDH and ICD which also 
showed that wild-type MDH and ICD purified from BL21(DE3) cells had no detectable 
acetylation [14,15].  
 
Figure 4.1. The incorporation of AcK at individual lysine sites of the CS. SDS/PAGE and 
western blotting analyses of purified CS and its variants from BL21(DE3) cells. Lane 1, wild-
type CS; lane 2, CS38AcK; lane 3, CS-168AcK; lane 4, CS-283AcK; lane 5; CS-295AcK; lane 
6, CS-310AcK; lane 7, CS-328AcK; lane 8, CS-356AcK; lane 9, CS-405AcK; lane 10, CS-
418AcK; lane 11, CS-422AcK. The same amounts of proteins were loaded. Anti-AcK: 
acetyllysine antibody. 
To facilitate the purification process and remove truncated proteins due to the usage of 
the UAG stop codon as the signal for AcK incorporation, we fused a His6-tag to the C terminus 
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of the CS. In this case, only site-specifically acetylated CS variants which had AcK at the 
position corresponding to the UAG stop codon could have the His6- tag and were able to be 
purified by affinity chromatography, while early terminated proteins had no such tags and were 
washed away during purification. Indeed, all the site-specifically acetylated CS variants had clear 
single bands and their acetylation were detected by the AcK antibody (Figure 4.1). The purity 
and sites of AcK incorporation were confirmed with full length MS and LC-MS/MS analyses, 
respectively (Figures 4.S1–4.S11).  
 
4.4.2 Characterizing the impact of lysine acetylation on the CS activity  
Under the standard CS enzyme assay condition containing 0.1 M KCl, enzyme activities of 
the wild-type CS and its site-specifically acetylated variants were measured (Figure 4.2A). 
Except for K283 (P = 0.0005) and K295 (P < 0.0001), all other variants did not have 
significantly different activities with that of the wild-type CS. Interestingly, acetylation at K283 
increased the activity by nearly twofold, while acetylation at K295 decreased the activity by 
about 10-fold. Since acetylation could occur at multiple lysine residues in the same protein, we 
also generated a dual-acetylated variant at K283 and K295 simultaneously by the genetic code 
expansion strategy [28], which still had a significant activity loss (P < 0.0001), implying the key 
role of acetylation at K295 in regulating CS enzyme activities. To exclude the possibility that the 
decreased activity was caused by mis-folding of the acetylated variant, we performed circular 
dichroism (CD) analysis of the CS-295AcK variant. The CD spectrum of the variant was highly 
similar to that of the wild-type CS, indicating that AcK incorporation did not affect the proper 
folding of the enzyme, and the activity loss should be caused by the impact of acetylation on the 
CS directly (Figure 4.S17).  
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To further study the effect of lysine acetylation at K283 and K295 on CS activities, 
steady-state kinetic analyses were performed (Table 4.1). Clearly, the binding of acetyl CoA was 
the major cause for activity changes. Acetylation of K283 facilitated the acetyl CoA binding, 
while acetylation of K295 impaired the binding of acetyl CoA.  
 
Figure 4.2 Characterization of the CS and its acetylated variants. (A) Relative enzyme 
activities. The activity of the wild-type (WT) Escherichia coli CS was set as 1. Mean values and 
standard deviations were calculated based on three replicates (n = 3). Two-tailed P values were 
determined by the t-test, and the significance level is 0.05. 
The allosteric inhibition by NADH is a unique feature for the E. coli Type II CS [5]. For 
this purpose, NADH inhibition tests were performed on those acetylated variants (Table 4.1). 
K168 is known to bind NADH directly, so the CS-168AcK variant was included in the test as a 
control. Indeed, the CS-283AcK variant had stronger resistance to NADH than the wild-type CS, 
which supported our hypothesis. On the other hand, the CS-295AcK variant was still sensitive to 
NADH.  
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Table 4.1 Steady-state kinetic parameters of the CS and its acetylated variants. 
 
a Measured with 0.1 M KCl. b Acetyl CoA (AcCoA) was held at 1 mM. c OAA was held at 0.1 
mM. d Measured in absence of KCl. e Mean values and standard deviations were calculated based 
on three replicates (n = 3). The kinetic parameters were determined by nonlinear regression with 
software GRAFIT. 
To further study the acetylation of the CS in living cells, we performed in vivo studies. 
There were two differences between in vitro and in vivo experiments through this study. First, in 
vitro assays used BL21 (DE3) cells which have different acetate metabolism from K12 strains to 
express the wild-type CS and its acetylated variants in order to decrease the background of 
nonspecific acetylation, while the E. coli K12-derived BW25113 strain was used for in vivo 
studies. Second, the wild-type CS and its acetylated variants were overexpressed and fused with 
affinity tags for easy purification in in vitro experiments, while the native CS was used to 
eliminate possible impacts from affinity tags for all in vivo studies, which was purified by the 
established protocol [30]. First, we compared the acetylation levels of native CSs purified from 
BW25113 cells grown in the LB medium only and the LB medium with 0.2% glucose. The 
acetylation levels of purified native CSs were determined by western blotting (Figure 4.3A).  
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Figure 4.3 The effect of acetylation on the CS in vivo. (A) SDS/PAGE and western blotting of 
purified native CSs from BW25113 cells growth in the LB medium only or the LB medium with 
0.2% glucose (LB+Glc). The same amounts of proteins were loaded. (B) The enzyme activities 
of purified native CSs from the LB medium only or the LB medium with 0.2% glucose. The 
activity of the CS purified from the LB medium only was set as 1. Mean values and standard 
deviations were calculated based on three replicates (n = 3). Two-tailed P values were 
determined by the t-test, and the significance level is 0.05. 
Clearly, The CS from the LB medium containing glucose had a higher acetylation level 
than that from the LB medium only, which was consistent with previous proteomic studies. 
Then, we measured enzyme activities of both native CSs. The CS purified from the LB medium 
containing glucose lost more than 30%, a significant decrease (P = 0.0111) of the activity 
compared to that purified from the LB medium only (Figure 4.3B), which should be caused by 
the acetylation of K295 according to in vitro studies above. 
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Figure 4.4 Mapping of key lysine residues in CS structures. (A) The crystal structure of the 
Escherichia coli CS hexamer (PDB ID: 4G6B) with acetylation sites K283 and K295 labeled. 
Two subunits in one dimer were in green and blue separately. Other dimers were in gray. (B) 
The crystal structure of the A. aceti CS dimer (PDB ID: 2H12) with K302 (the counterpart of 
K295 in E. coli CS) labeled. Two subunits in one dimer were in green and blue separately. The 
acetyl CoA analog carboxymethyldethia-CoA was in purple. 
 
4.4.3 Identifying the mechanism of CS acetylation 
Next, we studied the acetylation process of the CS in E. coli. It is known that lysine 
acetylation in E. coli is generated by either enzymatic acetylation with acetyl CoA as the acetyl-
donor or nonenzymatic acetylation with acetyl-phosphate (AcP) as the acetyl-donor [11,12]. Till 
now, YfiQ is still the only well-known protein acetyltransferase (KAT) in E. coli [31]. Very 
recently, a proteomic study has identified four additional KATs (RimI, YiaC, YjaB, and PhnO) 
in E. coli. However, overexpression of those four KATs did not increase the acetylation level of 
the CS. Thus, we first tested the acetylation of the CS by YfiQ. For in vivo tests, the acetylation 
level of the native CS purified from the wild-type or ΔyfiQ of BW25113 cells grown in the 
glucose medium was determined by western blotting (Figure 4.5A). The inactivation of the yfiQ 
gene did not decrease the acetylation level of the CS, indicating that YfiQ is not responsible for 
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CS acetylation. Then, we performed in vitro acetylation assays. Again, the His6- tagged CS was 
overexpressed in BL21(DE3) cells for easy purification and a cleaner background of nonspecific 
acetylation. The purified CS was then treated with YifQ and 0.2 mM acetyl CoA for 1 h, which 
had no detectable acetylation, consistent with in vivo results above (Figure 4.5B). 
 
Figure 4.5 Acetylation of the CS by YfiQ. SDS/ PAGE and western blotting. (A) purified 
native CSs from the wild-type, ΔyfiQ, ΔcobB, and ΔyfiQ ΔcobB of BW25113 cells; (B) purified 
CS from BL21(DE3) cells treated with purified YfiQ and/or acetyl CoA in vitro. The same 
amounts of proteins were loaded. 
YfiQ belongs to the Gcn5-related N-acetyltransferase (GNAT) family. Besides YfiQ, 
there are 24 more GNAT family members in E. coli including those four recently identified 
KATs. Thus, we further tested all these 24 GNATs individually (Figure 4.6). However, none of 
them could acetylate the CS in vitro, implying that nonenzymatic acetylation plays the major role 
in acetylating the CS. 
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Figure 4.6 In vitro acetylation assays of CS with GNATs. SDS/PAGE and western blotting of 
purified CS from BL21(DE3) cells which was treated with 24 GNATs and acetyl CoA in vitro, 
individually. Lane -1 is purified CS treated with 0.2 mM acetyl CoA in vitro as a background 
control. Lane 0 is purified CS treated with 3 mM AcP in vitro as a positive control. Lane 1 to 24 
is purified CS treated with 0.2 mM acetyl CoA and ArgA, AstA, CitC, ElaA, MnaT, PanM, 
PhnO, RimI, RimJ, RimL, SpeG, TmcA, WecD, YafP, YedL, YhbS, YhhY, YiaC, YiiD, YjaB, 
YjdJ, YjhQ, YjgM, and YpeA, respectively. 
Thus, we then tested nonenzymatic acetylation of the CS by AcP. For in vivo tests, 
BW25113 cells with the deletion of the pta gene or the ackA gene were used. Pta is the 
phosphate acetyltransferase, catalyzing the reversible conversion between acetyl CoA and AcP, 
thus the Δpta strain has much lower AcP in cells [18,33]. On the other hand, AckA, an acetate 
kinase, catalyzes the conversion between acetate and AcP. Inactivation of the ackA gene 
accumulates AcP in a non-acetate medium [34]. Native CSs from the wildtype, Δpta, and ΔackA 
of BW25113 cells grown in the glucose medium were purified and tested by western blotting 
(Figure 4.7A). 
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Figure 4.7 Acetylation of the CS by AcP. SDS-PAGE and western blotting. (A) purified 
native CSs from the wild-type, Δpta, and ΔackA of BW25113 cells; (B) purified CS from 
BL21(DE3) cells treated with AcP in vitro. The same amounts of proteins were loaded. 
 Clearly, Δpta lowered while ΔackA increased the acetylation level, indicating that CS 
acetylation levels were correlated with intracellular AcP concentrations. For in vitro tests, the 
wild-type CS overexpressed in BL21 (DE3) cells with a clean acetylation background was 
purified and treated with 0.2 mM, 3mM, or 12 mM AcP, which corresponds to estimated 
intracellular AcP concentrations at the exponential phase, the stationary phase, or the AcP-
accumulating condition (ΔackA), respectively [18,33,35]. Western blotting results indicated that 
AcP itself could acetylate CS in dose- and time-dependent manners, supporting in vivo results 
above (Figure 4.7B). 
Next, we used MS analyses to determine acetylated lysine sites in the CS by the in vitro 
AcP-treatment. Besides the 10 lysine residues tested above, five additional positions at K7, K22, 
K56, K293, and K333 were also found to be acetylated (Figures 4.S12–4.S16). Among them, 
K22 and K333 have never been identified to be acetylated in cells by any E. coli acetylome 
studies, possibly because the acetylation at these sites had lower stoichiometry and/or could be 
deacetylated easily in cells. Reversely, the acetylation at K10, K105, and K357 of the CS from E. 
coli acetylome database was not identified in our in vitro tests. Although this could be caused by 
differences in strains, growth conditions, and mass spectrometry resolutions, it also implied the 
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possible existence of additional KATs or cofactors needed specifically for these lysine sites in 
vivo. 
 
4.4.4 Exploring the mechanism of CS deacetylation  
Acetylation of certain lysine residues is a reversible process and could be removed by lysine 
deacetylases (KDACs). Although there are many types of KDACs in eukaryotic cells, the CobB 
protein, a homolog of sirtuin, is still the only known KDAC in E. coli [37,38]. Thus, we first 
tested the deacetylation of the CS by CobB. For in vivo tests, the acetylation levels of native CSs 
purified from the wild-type and ΔcobB of BW25113 cells grown in the glucose medium were 
compared by western blotting (Figure 4.5A). The deletion of cobB increased the CS acetylation, 
indicating that CobB could deacetylate the CS in vivo. We also determined the acetylation level 
of the native CS from cells with both genes of yfiQ and cobB inactivated (Figure 4.5A). The 
deletion of yfiQ could not decrease the CS acetylation level in the absence of CobB, confirming 
that YfiQ is not responsible for CS acetylation.  
The in vivo study above could not provide information of the sensitivities of individual 
acetylated lysine sites against the CobB deacetylase. Since we could generate site-specifically 
acetylated CS variants, we performed in vitro deacetylation experiments for this purpose. Each 
site-specifically acetylated CS variants expressed and purified from BL21(DE3) cells were 
treated with the purified CobB protein. Western blotting was used to determine their acetylation 
levels before and after the treatment (Figure 4.8A).  
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Figure 4.8 Deacetylation of the CS. (A) Western blotting of site-specifically acetylated CS 
variants treated with CobB in vitro. Numbers are the positions of acetylated lysine residues. The 
same amounts of proteins were loaded. (B) Mapping of lysine residues sensitive to CobB; (C) 
Mapping of lysine residues resistant to CobB; (D) Mapping of K356 on the crystal structure of 
the Escherichia coli CS hexamer (PDB ID: 4G6B). Two subunits in one dimer were in green and 
blue separately. Other dimers were in gray. Lysine residues and the mobile loop were marked 
with red. In the active form the CS, the mobile loop is proposed to move as the arrow shows. 
Most of the lysine sites were sensitive to CobB, but we did observe that three positions 
K168, K356, and K405 could resist CobB. Lysine residues tested were mapped onto the crystal 
structure of the CS [3]. CobB-sensitive sites (K38, K283, K295, K310, K328, K418, and K422) 
are all located at the CS surface (Figure 4.8B), which is a common feature for CobB-sensitive 
lysine residues.  
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Figure 4.9 The enzyme activities of purified CSs from the LB medium only or the LB 
medium with 0.2% glucose before and after 1-h CobB treatment. The activity of CS purified 
from the LB medium only was set as 1. Mean values and standard deviations were calculated 
based on three replicates (n = 3). 
Enzyme assays above showed that the CS activity was decreased by higher acetylation 
levels, largely due to the acetylation at K295 (Figures 4.2 and 4.4B). To confirm that the activity 
loss was caused by acetylation indeed, we treated the native CS purified from the glucose 
medium with the CobB protein, then measured its activity (Figure 4.9). The CS activity was 
restored, which could be explained by the fact that K295 is sensitive to CobB (Figure 4.8A), and 
the deacetylation of K295 frees the lysine residue for the proper binding with acetyl CoA. 
 
4.5 Discussion  
There have been a number of E. coli acetylome studies, but the sets of identified acetylated 
lysine residues in the E. coli CS are quite different (from only one site to as many as 11 
positions) and not well overlapped, largely due to the differences in strains, growth conditions or 
stages, acetylated peptide enrichment approaches, and mass spectrometry (MS) detection 
methods and resolutions [16,18,19]. Recently, several quantitative mass spectrometry studies of 
acetylation in E. coli have showed that the CS has much higher stoichiometry of acetylation than 
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many other E. coli proteins [24–26]. Due to the presence of multiple positions for acetylation, 10 
lysine residues were selected based on the criteria mentioned above. 
Interestingly, based on the crystal structure of the CS, both K283 and K295 are located in 
the ‘mobile loop’ (residues 267–297), which forms part of the acetyl CoA-binding site (Figure 
4.3A) [6]. The binding of NADH affects the refolding of the mobile loop to form the acetyl 
CoA-binding site. The CS from A. aceti is also a hexamer but is insensitive to NADH [7]. The 
counterpart of the mobile loop in the A. aceti CS is highly ordered, which could explain its 
resistance to NADH [7]. So, we proposed that the acetylation of K283 could induce the mobile 
loop to form a more ordered structure, thus facilitating the acetyl CoA binding.  The counterpart 
of K295 in the A. aceti CS, K302, directly contacts with acetyl CoA [7] (Figure 4.3B). Thus, the 
loss of the enzyme activity in the CS-295AcK variant should be caused by the impaired acetyl 
CoA binding, and such loss could not be restored by the acetylation of K283 in the dual-
acetylated variant CS-238/295AcK (Figure 4.2). Reversely, the higher activity associated with 
acetylation of K283 also requires K295 to be unacetylated.  
Comparing CSs from different organisms, K295 is well conserved while K283 is not [3]. 
This is not surprising, as K295 (or its counterpart in the A. aceti CS, K302) directly contacts with 
acetyl CoA, while K283 might not be necessary in NADH-resistant CSs to form ordered 
structures for acetyl CoA binding (Figure 4.4). Recently, the human Type I CS was also shown 
to lose activity with higher acetylation levels [8]. However, the specific acetylation site(s) which 
caused such loss was not determined. Based on acetylome database, the counterpart of K295 in 
the human CS, K327, has also been identified to be acetylated, which could explain the activity 
loss. Thus, besides the overall dimer structures, two types of CSs might also share the regulatory 
mechanism by lysine acetylation. 
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Also, it has been observed that among the CobB-resistant sites, K168 is at the dimer– 
dimer interface for NADH binding, while K405 is located at the subunit–subunit interface of the 
dimer (Figure 4.8C). Both residues are not easily accessible for CobB to deacetylate. K356 is 
located at the surface of the CS. Besides the possible reason that CobB cannot recognize 
acetylated K356, another potential explanation is that the mobile loop does not form the proper 
binding site for acetyl CoA in the T state (the inactive form) which was shown in the crystal 
structure, while in the R state (the active form), the mobile loop will have a conformational 
change, which could bury the K356, thus blocking its contacts with CobB (Figure 4.8D).  
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CHAPTER V 
CONCLUSION AND FUTURE DIRECTIONS 
5.1 Conclusion 
The TCA cycle, for long, has been considered an interlink among other metabolic and 
regulatory pathways in an organism and the critical role played by this pathway is associated 
with the fitness of a cell. Several types of cancers, neurodegenerative disorders, and rare diseases 
have been implicated with TCA cycle and correspondingly, this has raised a number of new 
questions that lead to insights on the intricate and intertwining role of TCA cycle enzymes on the 
maintenance of cellular health for the sound functioning of an organism. In doing so, the critical 
role imposed by acetylation on these enzymes becomes imperative. However, the relationship 
between the enzymes and acetylation has not been fully explored.  
The major research focus of this dissertation was to reveal the consequences of acetylation on 
the enzyme activity of TCA cycle enzymes and in turn understand its impacts on the overall 
health of an organism. In this dissertation, we investigated the effects of acetylation on malate 
dehydrogenase, isocitrate dehydrogenase, and citrate synthase.  
To study the effects of acetylation on these enzymes the genetic code expansion strategy was 
used to incorporate lysine at specific positions in the protein. The tailor-made proteins were 
synthesized by site-directed mutations on the target gene to replace lysine with stop codons for 
AcK expression in E. coli. The pyrrolysyl-tRNA synthetase system was further developed 
through phage assisted evolution to create an efficient AcKRS system. Using this orthogonal 
translation machinery, the co-translation of AcK in desired proteins was made possible. 
Our findings from chapter 2 indicate that positions selected for acetylation in malate 
dehydrogenase either show increased enzyme activity or remain unaltered with acetylation. The 
 
113 
increased activity was rendered to the improved turnover of the enzyme and had no effects of the 
substrate bindings. CobB, a member of the bacterial situins family was specific to lysine residues 
K140 and K162 present on the surface. In human MDH, SIRT3 is functional and was specific to 
K307. Since all these positions were present on the unstructured regions of the enzyme, they 
were more prone to the action of situins. 
In chapter 3, we found that NAD+ dependent isozyme of isocitrate dehydrogenase (IDH3) 
takes part in energy production via TCA cycle and undergoes acetylation. Between prokaryotic 
and eukaryotic sequences that showed no similarity, 8 lysine residues were selected for 
acetylation. In IDH, an exception to the selection criteria was made by choosing K100 which is 
normally succinylated. K100 was selected as it is positioned such that it plays a commanding 
role in the catalysis and substrate binding of the enzyme. From chapter-1, it is evident that an 
enzyme could comprise of lysine residues that can both increase and decrease the enzyme 
activity, but the regulatory role of acetylated positions K100 and K230 which cause complete 
loss of enzyme activity has a stronger effect. The increase in enzyme activity caused by 
acetylation of K55 and K350 were attributed to the positioning of these residues. It can be 
deduced that the placement of K55 behind the active site causes its interaction with the other 
residues in the helices that form the active site. Similarly, K350 which is present on the entrance 
of the active site, due to the cancellation of the positive charge, may facilitate better binding of 
NADP+. As in the case of MDH, CobB was successful in deacetylating lysine residues present 
on the surface of the enzyme (K55, K142, K177, and K350). In this chapter, an important 
comparison was also made between using glutamine as an acetyllysine mimic and the direct 
incorporation of AcK into the protein co-translationally. It was inferred that the modulation in 
the enzyme activity between the two depended on the position of the residues. In the case of 
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position K242, the difference in the enzyme activity between the two methods seemed less but 
for residues K55 and K350 the difference in approaches had considerably large variations and 
also led to opposite effects in certain cases. This result implied that the use of glutamine as a 
mimic for AcK does not always function in the appropriate way and it cannot be used as a 
substitute for AcK. 
In chapter 4, the role of acetylation on citrate synthase was studied. Of the 10 selected 
residues that were acetylated only K283 and K295 showed variations in enzyme activity. The 
type II of citrate synthase (CS) undergoes allosteric inhibition with the binding of NADH. These 
positions, K283 and K295, are present in the mobile loop of the enzyme thereby facilitating 
acetyl CoA binding. Steady state kinetics for CS demonstrates the imposing role of acetyl CoA 
binding in causing the variations in enzyme activity. Correspondingly, when NADH binds, the 
refolding of mobile loop is affected and in turn, the binding of acetyl CoA. With duel acetylation 
incorporation of K283/K295, the regulatory role of K283 overpowers that of K295. This could 
also be the reason that K295 is conserved in many organisms while K283 is not. The role of 
K283 becomes unnecessary if the loop is well structured. Similar effects are verified in human 
CS where acetylation of the enzyme lowers the enzyme activity. This could suggest that the 
counterpart of K295 in humans, K327 could be acetylated. The action of CobB sirtuin 
deacetylase is different in CS when compared to MDH and IDH, in the sense that it acts on the 
residues on the surface with the exception of K356. The positions which are resistant to CobB 
are K168 (NADH binding site), K405 (dimer-dimer interface), and K356 (surface). It is 
comprehended that when CS is in the T-state or resting state, K356 is exposed to the surface as 
in the considered crystal structure (PDB ID: 4G6B) but in the R-state, this residue become buried 
in the sequence thereby evading the action of CobB.  
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With all the enzymes studied, the impact of glucose on acetylation was verified. It was 
observed that with increase in concentration of glucose in the growth media, there was dose-
dependent increase in the acetylation levels of the enzyme indicating the likely role of 
acetylation in facilitating cellular adaptations under varied conditions. This could be one of the 
reasons for the difference in acetylation profiles for different cells under diverse conditions of the 
same organism.  
The acetyl transferases of GNAT family consist of 25 members and interestingly, with 
further investigation, results showed that none of the 25 acetyltransferases play a role in the 
transfer of acetyl group in MDH, IDH or CS. This could probably be because of the presence of 
other unknown acetyl transferases or the non-enzymatic acetyl transfer. Non-enzymatic 
acetylation with acetyl phosphate (AcP) revealed that enzymes showed high acetylation levels. 
Additionally, several positions which were never reported in acetylome studies were also shown 
to be acetylated. 
 
5.2 Significance of This Dissertation 
A renewed interest has resulted in understanding the role of TCA cycle in the overall 
functioning of an organism. By studying the major modifications of the cycle, we can gain 
awareness on the mechanisms that underlie the astonishing spectrum of clinical abnormalities. In 
this dissertation, we highlighted a unique technique for the study of acetylation on different 
proteins and validated that the use of glutamine as a mimic for AcK is not recommended.  
Although many studies have identified acetylation sites across different domains of life for 
thousands of proteins, the role of these acetylation sites have not been well understood. As it is 
now clear that not all proteins are enzymatically acetylated, it would be vital to identify the 
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specificity of different acetyltransferases. We believe that the dynamic process of addition or 
removal of acetyl group can also be nutrient dependent, and we expect that these studies will 
support future researchers with improved insights on the mechanistic nature of acetylation. With 
the understanding gained from this work, a better focus on several disease models can be gained 
in the future. For instance, many proteins that are upregulated in various cancers can be 
controlled by recognizing which PTM of a specific amino acid could be modulated for this 
purpose. This method also paves a path for targeted drug delivery against pathogens which have 
their pathogenesis associated to a number of PTMs. 
 
5.3 Future Directions 
The insertion of a simple acetyl group can have dramatic effects on the functioning of a 
protein. The masking of the positive charge on lysine has been predominantly confirmed in 
histones, but non-histone protein acetylation has also been gaining great attention over the years. 
A number of such protein modifications are known to be conserved in eukaryotes, thus 
suggesting the importance of these amino acids in the functioning of a protein both 
biochemically and genetically. Hence, expansion of our knowledge on acetylation in eukaryotes 
will be significant.  
Additionally, PTMs are dynamic and multiple PTMs can crosstalk to perform a specific role. 
In many cases such as autophagy, phosphorylation precedes acetylation for subsequent actions. 
Sometimes, several modifications such as acetylation, methylation, and ubiquitination can 
compete for a lysine residue. When a given residue is modified it blocks other modifications. 
Such conditions are typically established in protein p53. Once the lysine residue is acetylated, it 
blocks the interception of both ubiquitination and methylation. There are many such proteins that 
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are yet to be explored for such signaling cascades. It will also be useful to develop deeper 
insights on acetylation profiles of cells in response to a stimulus in a dynamic manner.  
The role of acetylation on mitochondrial proteins is a field that has developed recent attention 
and advanced studies have to be undertaken to unravel the full potential of mitochondrial 
functions. Furthermore, in today’s world, we are yet to fully encompass the basic biology of 
protein acetylation, especially in eukaryotes. Acetylated proteins could serve as biomarkers for 
various disease conditions and with the advancing technology it has the potential to aid in the 
development of diagnostic, prognostic, and therapeutic tools. 
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Supplementary Data  
Supplementary Data for Chapter 2 
Table 2.S1. The list of strains with plasmids used in this study. 
 
*: OTS is the abbreviation for orthogonal translational modification. 
  
Strain Plasmid 
  
Top10 pBAD-eMDH 
  
Top10 pBAD-hMDH2 
   
Top10 cobB pBAD-eMDH 
   
Top10 cobB pBAD-hMDH2 
  
Top10  cobB  patZ pBAD-eMDH 
  
Top10 pBAD-eMDH(140TAG) + pTech-AcK-OTS* 
   
Top10 cobB pBAD-eMDH(140TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-eMDH 
  
BL21(DE3) pET15a-eMDH(99TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-eMDH(140TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-eMDH(162TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-hMDH2 
  
BL21(DE3) pET15a-hMDH2(185TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-hMDH2(301TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-hMDH2(307TAG) + pTech-AcK-OTS 
  
BL21(DE3) pET15a-hMDH2(314TAG) + pTech-AcK-OTS 
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Figure 2.S1. The alignment of protein sequences of E. coli MDH and human MDH2. The 
selected acetylation sites in E. coli MDH are marked by *, and those in human MDH2 are 
marked by #. 
 
 
Figure 2.S2. LC-MS/MS analysis of E. coli MDH 99-AcK. The tandem mass spectrum of the 
peptide (residues 88-107) SDLFNVNAGIVK*NLVQQVAK (ion score 79) from purified eMDH 
with one amber codon at position 99. K* denotes AcK incorporation. The partial sequence of the 
peptide containing the AcK can be read from the annotated b or y ion series. 
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Figure 2.S3. LC-MS/MS analysis of E. coli MDH 140-AcK. The tandem mass spectrum of the 
peptides (residues 135-153) AGVYDK*NKLFGVTTLDIIR (ion score 45) from purified eMDH 
with one amber codon at position 140. K* denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated b or y ion series. 
 
 
Figure 2.S4. LC-MS/MS analysis of E. coli MDH 162-AcK. The tandem mass spectrum of the 
peptides (residues 154-164) SNTFVAELK*GK (ion score 74) from purified eMDH with one 
amber codon at position 162. K* denotes AcK incorporation. The partial sequence of the peptide 
containing the AcK can be read from the annotated b or y ion series. 
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Figure 2.S5. LC-MS/MS analysis of human MDH2 185-AcK. The tandem mass spectrum of 
the peptides (residues 177-191) ANTFVAELK*GLDPAR (ion score 99) from purified hMDH2 
with one amber codon at position 185. K* denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated b or y ion series. 
 
 
Figure 2.S6. LC-MS/MS analysis of human MDH2 301-AcK. The tandem mass spectrum of 
the peptides (residues 298-307) GIEK*NLGIGK (ion score 75) from purified hMDH2 with one 
amber codon at position 301. K* denotes AcK incorporation. The partial sequence of the peptide 
containing the AcK can be read from the annotated b or y ion series. 
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Figure 2.S7. LC-MS/MS analysis of human MDH2 307-AcK. The tandem mass spectrum of 
the peptides (residues 302-314) NLGIGK*VSSFEEK (ion score 90) from purified hMDH2 with 
one amber codon at position 307. K* denotes AcK incorporation. The partial sequence of the 
peptide containing the AcK can be read from the annotated b or y ion series. 
 
 
Figure 2.S8. LC-MS/MS analysis of human MDH2 314-AcK. The tandem mass spectrum of 
the peptides (residues 308-324) VSSFEEK*MISDAIPELK (ion score 79) from purified hMDH2 
with one amber codon at position 314. K* denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated b or y ion series. 
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Figure 2.S9. Western blotting of acetylated hMDH2 variants treated with SIRT3. The 
acetylation levels of hMDH2 variants after 2-hour incubation were compared with those without 
SIRT3 treatment. The reaction was performed in buffer contains 40 mM HEPES (pH 7.0), 6 mM 
MgCl2, 1.0 mM NAD
+, 1 mM DTT and 10 % glycerol. 10 μg hMDH2 variants, 10 μg SIRT3, 
and the reaction buffer were incubated at 37 °C in a total volume of 100 μl. 
 
 
 
 
Figure S10. In vitro acetylation of E. coli MDH by 25 GNAT family members. Western 
blotting of purified eMDH from BL21(DE3) cells treated with candidate acetyltransferases and 
acetyl CoA for 2 hours. The same amounts of proteins were loaded. Lane 1 is eMDH incubated 
with acetyl CoA only; the proteins from Lane 2 to Lane 26 are YiaC, YjhQ, YhbS, YafP, ElaA, 
YjdJ, YedL, YpeA, YhhY, YjaB, YiiD, YjgM, WecD, ArgA, AstA, CitC, MnaT, PanM, PhnO, 
RimI, RimJ, RimL, SpeG, TmcA, and YfiQ, individually. The bands at other sizes indicated the 
acetylation of candidate acetyltransferases. 
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Supplementary Data for Chapter 3 
Table 3.S1. The list of strains with plasmids used in this study. 
 
*: OTS is the abbreviation for orthogonal translational modification. 
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Figure 3.S1. LC-MS/MS analysis of ICDH 55-AcK. The tandem mass spectrum of the peptide 
(residues 48- 61) VVDAAVEKACAYKGER from purified ICDH 55-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure 3.S2. LC-MS/MS analysis of ICDH 100-AcK. The tandem mass spectrum of the 
peptide (residues 97- 112) VAIKACGPLTTPVGGGIR from purified ICDH 100-AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated b or y ion series. Matched peaks are in red. 
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Figure 3.S3. LC-MS/MS analysis of ICDH 142-AcK. The tandem mass spectrum of the 
peptide (residues 133-153) YYQGTPSPVKACHPELTDMVIFR from purified ICDH 142-AcK. 
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be 
read from the annotated a, b or y ion series. Matched peaks are in red.  
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Figure 3.S4. LC-MS/MS analysis of ICDH 177-AcK. The tandem mass spectrum of the 
peptide (residues 175-180) VIKACFLR from purified ICDH 177-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure S5. LC-MS/MS analysis of ICDH 230-AcK. The tandem mass spectrum of the peptide 
(residues 223-235) DSVTLVHKACGNIMK from purified ICDH 230-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 3.S6. LC-MS/MS analysis of ICDH 235-AcK. The tandem mass spectrum of the 
peptide (residues 231-242) GNIMKACFTEGAFK from purified ICDH 235-AcK. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure 3.S7. LC-MS/MS analysis of ICDH 242- AcK. The tandem mass spectrum of the 
peptide (residues 236-250) FTEGAFKACDWGYQLAR from purified ICDH 242-AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated y ion series. Matched peaks are in red. 
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Figure 3.S8. LC-MS/MS analysis of ICDH 350-AcK. The tandem mass spectrum of the 
peptide (residues 345-365) YAGQDKACVNPGSIILSAEMMLR from purified ICDH 350-AcK. 
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be 
read from the annotated a, b or y ion series. Matched peaks are in red.  
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Figure 3.S9. MALDI-TOF mass spectra. Purified wild-type ICDH (upper) and ICDH 55-AcK 
(lower) as a representative acetylated ICDH variant. The single weak of acetylated ICDH 
indicated homogeneous incorporation of acetyllysine. 
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Figure 3.S10. LC-MS/MS analysis of ICDH 55AcK/100AcK. The tandem mass spectrum of 
the peptide (residues 48-58) VVDAAVEKACAYK (upper) and the peptide (residues 97-112) 
VAIKACGPLTTPVGGGIR (lower) from the purified ICDH 55AcK/100AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. 
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Figure 3.S11. LC-MS/MS analysis of ICDH 55AcK/142AcK. The tandem mass spectrum of 
the peptide (residues 48-58) VVDAAVEKACAYK (upper) and the peptide (residues 133-153) 
YYQGTPSPVKACHPELTDMVIFR (lower) from the purified ICDH 55AcK/142AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated a, b or y ion series. 
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Figure 3.S12. LC-MS/MS analysis of ICDH 55AcK/177AcK. The tandem mass spectrum of 
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 167-
180) ADSADAEKVIKACFLR (lower) from the purified ICDH 55AcK/177AcK. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. 
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Figure 3.S13. LC-MS/MS analysis of ICDH 55AcK/230AcK. The tandem mass spectrum of 
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 212- 
230) AAIEYAIANDRDSVTLVHKAC (lower) from the purified ICDH 55AcK/230AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated a, b or y ion series. 
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Figure 3.S14. LC-MS/MS analysis of ICDH 55AcK/235AcK. The tandem mass spectrum of 
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 231-
250) GNIMKACFTEGAFKDWGYQLAR (lower) from the purified ICDH 55AcK/235AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated a, b or y ion series. 
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Figure 3.S15. LC-MS/MS analysis of ICDH 55AcK/242AcK. The tandem mass spectrum of 
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 236-
250) FTEGAFKACDWGYQLAR (lower) from the purified ICDH 55AcK/242AcK. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. 
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Figure 3.S16. LC-MS/MS analysis of ICDH 55AcK/350AcK. The tandem mass spectrum of 
the peptide (residues 48-61) VVDAAVEKACAYKGER (upper) and the peptide (residues 345-
365) YAGQDKACVNPGSIILSAEMMLR (lower) from the purified ICDH 55AcK/350AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated a, b or y ion series. 
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Figure 3.S17. MALDI- TOF mass spectra. Purified wild-type ICDH (upper) and ICDH 
55AcK/100AcK (lower) as a representative dual-acetylated ICDH variant. The single weak of 
dual-acetylated ICDH indicated simultaneous incorporation of acetyllysine at two lysine sites. 
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Figure 3.S18. Mapping of acetylation sites on the crystal structure of ICDH. The crystal 
structure of the ICDH dimer (PDB ID: 4aj3) was demonstrated with the selected acetylation sites 
labelled. Two subunits were colored with red and blue separately. 
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Figure 3.S19. In vitro deacetylation of RutR by YcgC. SDS-PAGE and western blotting of 
RutR treated with the YcgC protein. 
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Figure 3.S20. In vitro acetylation assays of ICDH with YfiQ. A) SDS-PAGE and western 
blotting of ICDH treated with the YfiQ protein and 200 µM acetyl- CoA. B) SDS-PAGE and 
western blotting of RcsB treated with the YfiQ protein. RcsB is a known substrate of YfiQ and 
was used to show the purified YfiQ protein was active. 
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Figure 3.S21. LC-MS/MS spectrum of the peptide (residues 1-12). MESKACVVVPAQGK 
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated a, b or y ion series. Matched 
peaks are in red. 
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Figure 3.S22. LC-MS/MS spectrum of the peptide (residues 14-47). ITLQNGKAC 
LNVPENPIIP-YIEGDGIGVDVTPAMLK from acetyl-phosphate-treated ICDH. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure 3.S22. LC-MS/MS spectrum of the peptide (residues 14-47).  (Cont)ITLQNGKAC 
LNVPENPIIP-YIEGDGIGVDVTPAMLK from acetyl-phosphate-treated ICDH. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure 3.S23. LC-MS/MS spectrum. Peptide (residues 21-55) LNVPENPIIPYIEGDGIGVDV-
TPAMLKACVVDAAVEK from acetyl-phosphate-treated ICDH. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 3.S23. LC-MS/MS spectrum (Cont.). Peptide (residues 21-55) 
LNVPENPIIPYIEGDGIGVDV-TPAMLKACVVDAAVEK from acetyl-phosphate-treated 
ICDH. KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK 
can be read from the annotated b or y ion series. Matched peaks are in red. 
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Figure 3.S24. LC-MS/MS spectrum. Peptide (residues 73-84) KACISWMEIYTGEK from 
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the 
peptide containing the AcK can be read from the annotated a, b or y ion series. Matched peaks 
are in red. 
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Figure 3.S25. LC-MS/MS spectrum. Peptide (residues 154-174) ENSEDIYAGIEWKACAD-
SADAEK from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial 
sequence of the peptide containing the AcK can be read from the annotated b or y ion series. 
Matched peaks are in red.  
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Figure 3.S26. LC-MS/MS spectrum. Peptide (residues 167-177) ADSADAEKACVIK from 
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the 
peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks are 
in red. 
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Figure 3.S27. LC-MS/MS spectrum. Peptide (residues 251-267) EEFGGELIDGGPWLKACVK 
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks 
are in red. 
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Figure 3.S28. LC-MS/MS spectrum. Peptide (residues 268-278) NPNTGKACEIVIK from 
acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of the 
peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks are 
in red. 
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Figure 3.S29. LC-MS/MS spectrum. Peptide (residues 274-292) 
EIVIKACDVIADAFLQQILLR from acetyl-phosphate-treated ICDH. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated a, b or y ion series. Matched peaks are in red. 
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Figure 3.S30. LC-MS/MS spectrum. Peptide (residues 366- 387) 
HMGWTEAADLIVKACGME-GAINAK from acetyl-phosphate-treated ICDH. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red.  
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Figure S31. LC-MS/MS spectrum. Peptide (residues 379-395) GMEGAINAKACTVTYDFER 
from acetyl-phosphate-treated ICDH. KAC denotes AcK incorporation. The partial sequence of 
the peptide containing the AcK can be read from the annotated b or y ion series. Matched peaks 
are in red.  
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Table 4.S1. The list of strains with plasmids used in this study. 
Strain Plasmid or Sources 
BW25113 Lab directory 
BW25113 Keio collection 
BW25113 Keio collection 
BW25113 Keio collection 
BW25113 Keio collection 
BW25113 Keio collection 
BW25113 Lab directory 
AG1 pCA24N-CobB (AKSA collection) 
AG1 pCA24N-YfiQ (AKSA collection) 
AG1 pCA24N-RcsB (AKSA collection) 
BL21(DE3) pCDF-CS 
BL21(DE3) pCDF-CS (38TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (168TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (283TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (295TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (310TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (328TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (356TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (405TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (418TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (422TAG) + pTech-AcK-OTS 
BL21(DE3) pCDF-CS (283TAG/295TAG) + pTech-AcK-OTS 
 
*: OTS is the abbreviation for orthogonal translational modification. 
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47919 
 
Figure 4.S1. MALDI -TOF mass spectra of CS. Purified wild-type CS (upper, 47878 Da) and 
CS 38-AcK (lower, 47919 Da) as a representative of acetylated CS variants. The single peak of 
acetylated CS (ΔMW = 41 Da) indicated homogeneous incorporation of acetyllysine.  
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Figure 4.S2. LC-MS/MS analysis of CS 38-AcK. The tandem mass spectrum of the peptide 
(residues 34-56) TLGSKAC GVFTFDPGFTSTASCESK from purified CS 38-AcK. KAC denotes 
AcK incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red.  
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Figure 4.S3. LC-MS/MS analysis of CS 168- AcK. The tandem mass spectrum of the peptide 
(residues 165-178) LLSKACMPTMAAMCYK from purified CS 168-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S4. LC-MS/MS analysis of CS 283-AcK. The tandem mass spectrum of the peptide 
(residues 275-290) MLEEISSVKACHIPEFVR from purified CS 283-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S5. LC-MS/MS analysis of CS 295-AcK. The tandem mass spectrum of the peptide 
(residues 292-300) AKDKACNDSFR from purified CS 295-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S6. LC-MS/MS analysis of CS 310-AcK. The tandem mass spectrum of the peptide 
(residues 308-315) VYKACNYDPR from purified CS 310-AcK. KAC denotes AcK incorporation. 
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion 
series. Matched peaks are in red. 
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Figure 4.S7. LC-MS/MS analysis of CS 328-AcK. The tandem mass spectrum of the peptide 
(residues 321-333) ETCHEVLKACELGTK from purified CS 328-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S8. LC-MS/MS analysis of CS 356-AcK. The tandem mass spectrum of the peptide 
(residues 334-357) DDLLEVAMELENIALNDPYFIEKACK from purified CS 356-AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated b or y ion series. Matched peaks are in red.  
 
167 
 
 
 
Figure 4.S9. LC-MS/MS analysis of CS 405-AcK. The tandem mass spectrum of the peptide 
(residues 389-408) TVGWIAHWSEMHSDGMKACIAR from purified CS 405-AcK. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated b or y ion series. Matched peaks are in red.  
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Figure 4.S10. LC-MS/MS analysis of CS 418-AcK. The tandem mass spectrum of the peptide 
(residues 411-422) QLYTGYEKACRDFK from purified CS 418-AcK. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S11. LC-MS/MS analysis of CS 422-AcK. The tandem mass spectrum of the peptide 
(residues 420-426) DFKACSDIK from purified CS 422-AcK. KAC denotes AcK incorporation. 
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion 
series. Matched peaks are in red. 
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Figure 4.S12. LC-MS/MS analysis of CS 7-AcK. The tandem mass spectrum of the peptide 
(residues 6-22) AKACLTLNGDTAVELDVLK from the AcP-treated CS. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S13. LC-MS/MS analysis of CS 22-AcK. The tandem mass spectrum of the peptide 
(residues 8-33) LTLNGDTAVELDVLKACGTLGQDVIDIR from the AcP-treated CS. KAC 
denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be read 
from the annotated b or y ion series. Matched peaks are in red.  
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Figure 4.S14. LC- MS/MS analysis of CS 56-AcK. The tandem mass spectrum of the peptide 
(residues 39- 56) GVFTFDPGFTSTASCESKAC from the AcP-treated CS. KAC denotes AcK 
incorporation. The partial sequence of the peptide containing the AcK can be read from the 
annotated b or y ion series. Matched peaks are in red. 
  
 
173 
 
 
 
Figure 4.S15. LC-MS/MS analysis of CS 293- AcK. The tandem mass spectrum of the peptide 
(residues 292-300) AKACDKNDSFR from the AcP-treated CS. KAC denotes AcK incorporation. 
The partial sequence of the peptide containing the AcK can be read from the annotated b or y ion 
series. Matched peaks are in red. 
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Figure 4.S16. LC-MS/MS analysis of CS 333-AcK. The tandem mass spectrum of the peptide 
(residues 329-356) ELGTKACDDLLEVAMELENIALNDPYFIEK from the AcP-treated CS. 
KAC denotes AcK incorporation. The partial sequence of the peptide containing the AcK can be 
read from the annotated b or y ion series. Matched peaks are in red. 
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Figure 4.S17. The CD spectra were recorded on a J-1500 CD Spectrometer (JASCO 
Corporation, Tokyo, Japan). Purified enzymes were diluted to a concentration of 0.1 mg/mL in 
5 mM Tris/HCl pH 7.8, 0.1 M KCl, and scanned from 190 nm to 250 nm with a 20 nm/min 
speed. Scanning was performed three times for each sample and the average was plotted. 
